Compounds and methods for treating Duchenne muscular dystrophy

By designing single-stranded oligonucleotide compounds targeting premRNA of dystrophin, the cellular uptake and biodistribution problems of existing exon jump oligonucleotides in the treatment of Duchenne muscular dystrophy are solved, and the problem of cellular uptake and biodistribution of existing exon-hopping oligonucleotides in the treatment of Duchenne muscular dystrophy is achieved. It can improve the level of dystrophin in DMD patients and delay disease progression.

CN115348883BActive Publication Date: 2024-11-15NOVARTIS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080093533.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-11-27
Filing Date
2020-11-25
Publication Date
2024-11-15
Estimated Expiration
2040-11-25

AI Technical Summary

Technical Problem

Existing exon-hopping oligonucleotides have cellular uptake and biodistribution challenges in the treatment of Duchenne muscular dystrophy, resulting in a lack of sufficient evidence for clinical benefits and limited impact on disease progression in patients with DMD.

Method used

Provided is a single-stranded oligonucleotide compound including covalently linked to an uptake motif that targets dystrophin promRNA to induce muscle by contacting cells, exon jumping, or administration to a subject Exon jump of dystrophic protein premRNA, used to treat Duchenne muscular dystrophy.

Benefits of technology

By increasing the expression levels of dystrophins intracellular and potentially delaying muscle mass loss and disease progression, a potential therapeutic strategy is provided to improve survival in DMD patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003750304920000082
    Figure BDA0003750304920000082
  • Figure BDA0003750304920000332
    Figure BDA0003750304920000332
  • Figure BDA0003750304920000334
    Figure BDA0003750304920000334
Patent Text Reader

Abstract

Disclosed herein are compounds including a single-stranded oligonucleotide (A) having a nucleobase sequence complementary to a portion of dystrophin pre-mRNA, their preparation, and their use for treating Duchenne muscular dystrophy.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 941,549, filed on November 27, 2019, which is incorporated herein in its entirety for all purposes.

[0003] A "sequence listing", table or computer submitted as an ASCII file

[0004] References to the Program Listing Appendix

[0005] The sequence listing prepared in file DTX-004-01WO_ST25.TXT, created on November 20, 2020, is 46,377 bytes in size and is in the machine format of IBM-PC, MS Windows operating system, and is incorporated herein by reference.

[0006] background Technical Field

[0007] The present disclosure relates to the field of biologically active compounds comprising single-stranded oligonucleotides. More specifically, the present disclosure relates to compounds comprising single-stranded oligonucleotides that target the dystrophin gene and their use in treating Duchenne muscular dystrophy. Background Art

[0008] Duchenne muscular dystrophy (DMD) is an X-linked fatal muscle disease affecting approximately 1 in 5,000 newborn boys (Fairclough et al., 2013, " Natural Review of Genetics (Nat Rev Genet.) ", 14: 373-378), and is caused by mutations in the dystrophin gene (Hoffman et al., 1987, " Cell (Cell) ", 51: 919-928). The loss of functional dystrophin is mainly caused by frameshift mutations in the gene. Dystrophin is a key component of the dystrophin-associated glycoprotein complex (DGC), which connects the sarcolemma and the extracellular matrix to the actin cytoskeleton, thereby maintaining myocyte membrane integrity during contraction. In the absence of functional dystrophin, DMD patients begin to show skeletal muscle weakness in early childhood. As patients age, they develop progressive loss of muscle mass, spinal curvature (kyphosis), paralysis, and typically cannot survive past 30 years of age and die from cardiac and respiratory complications of severe muscle weakness (Matsumura et al., 2011, " Clinical Neurology (Rinsho Shinkeigaku)", 51:743-750). Although genetic causes have been known for decades, there is currently no method for curing DMD, and approved therapies have limited efficacy (Landfeldt et al., 2014, " Neurology (Neurology)", 83:529-536).

[0009] A therapeutic strategy of considerable interest is the use of a type of splice-switching oligonucleotide, the exon-skipping oligonucleotide, to restore at least partial levels of dystrophin. Exon-skipping antisense oligonucleotides are designed to hybridize to a selected exon and mask the splicing signal of the selected exon, preventing its inclusion in the final mRNA (i.e., inducing "skipping" of the exon) and resulting in the production of a protein that is in frame, albeit shorter, but functional. The target exon is selected based on the nature of the mutation and the resulting translation product, e.g., a mutation that results in premature stop codon translation. In the case of dystrophin, exon-skipping oligonucleotides that target the selected splicing signal of the dystrophin pre-mRNA result in exon skipping and translation of a shorter, but at least partially functional, dystrophin protein.

[0010] The splicing alteration strategy appears to be applicable to the majority of DMD patients (-83%) (Aartsma et al., 2009, Hum Mut., 2009, 30(3):293-299), and several clinical development programs are evaluating exon-skipping oligonucleotides targeting different mutations in the dystrophin gene. One such program at Sarepta Therapeutics resulted in the approval of the first exon-skipping oligonucleotide for the treatment of DMD, EXONDYS51. TM EXONDYS51 is indicated for patients with DMD whose dystrophin gene contains a mutation suitable for exon 51 skipping. TM Hybridizes with exon 51 of the dystrophin pre-mRNA, resulting in the exclusion of exon 51 during mRNA processing and translation of an internally truncated dystrophin protein. Although EXONDYS51 has been found TM Increases dystrophin levels in the muscles of DMD patients, but clinical benefit remains to be fully demonstrated. Other clinical programs based on exon-skipping oligonucleotides are underway. Despite the activity in this therapeutic area, no exon-skipping oligonucleotide has shown clinical benefit to date. In addition, EXONDYS51 TM and other exon-skipping oligonucleotides are limited by cellular uptake and biodistribution challenges. Therefore, there remains a need for exon-skipping oligonucleotides targeting dystrophin that have a meaningful impact on disease progression in DMD patients. Summary of the Invention

[0011] Provided herein are, among other things, compounds or compounds comprising a single-stranded oligonucleotide (A) covalently linked to an uptake motif, wherein the single-stranded oligonucleotide targets dystrophin pre-mRNA.

[0012] In an embodiment, the uptake motif has the following structure:

[0013] .t is an integer from 1 to 5.

[0014] A is a single-stranded oligonucleotide having a nucleobase sequence complementary to dystrophin pre-mRNA. 3 and L 4 L is independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO2-O-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene. 5 Yes-L5A -L 5B -L 5C -L 5D -L 5E -.L 6 Yes-L 6A -L 6B -L 6C -L 6D -L 6E -.

[0015] L 5A , L 5B , L 5C , L 5D , L 5E , L 6A , L 6B , L 6C , L 6D and L 6E and -S- are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0016] R 1 and R 2 are independently unsubstituted C1-C 25 Alkyl, where R 1 and R 2 At least one of them is unsubstituted C9-C 19 Alkyl. R 3 is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0017] In one aspect, a method is provided comprising contacting a cell with a compound as described herein or a compound comprising a single-stranded oligonucleotide (A).

[0018] In one aspect, a method is provided for inducing exon skipping of dystrophin pre-mRNA in a cell, comprising contacting the cell with a compound as described herein or a compound comprising (A).

[0019] In one aspect, methods are provided comprising administering to a subject a compound as described herein or a compound comprising a single stranded oligonucleotide (A).

[0020] In one aspect, a method is provided comprising administering to a subject a compound as described herein or a compound comprising a single-stranded oligonucleotide (A). The method comprises administering to a subject having a mutation in a dystrophin gene that is suitable for exon skipping.

[0021] In one aspect, there is provided a compound as described herein or a compound comprising a single stranded oligonucleotide (A) for use in therapy.

[0022] In one aspect, a method of introducing a single-stranded oligonucleotide into a cell in a subject is provided. The method comprises administering to the subject a compound comprising a single-stranded oligonucleotide (A) as described herein.

[0023] In one aspect, a pharmaceutical composition is provided comprising a pharmaceutically acceptable excipient and a compound as described herein comprising a single-stranded oligonucleotide (A).

[0024] Other aspects are disclosed below. DETAILED DESCRIPTION

[0025] definition

[0026] Unless otherwise defined, all technical terms, scientific terms, abbreviations, chemical structures and chemical formulas used herein have the same meaning as those generally understood by those of ordinary skill in the art. The chemical structures and chemical formulas described herein are constructed according to standard rules of chemical valence known in the chemical field. Unless otherwise indicated, all patents, applications, published applications and other publications cited herein are incorporated by reference in their entirety. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA technology and pharmacology are used. In addition, the use of the term "including" and other forms such as "include," "includes," and "included" is not restrictive. As used in this specification, whether in transitional phrases or in the body of the claims, the terms "comprise(s)" and "comprising" should be interpreted as having an open meaning. That is, the term should be interpreted as synonymous with the phrase "at least having" or "at least including." When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound, composition, or device, the term "comprising" means that the compound, composition, or device includes at least the recited features or components, but may also include additional features or components.

[0027] When substituents are designated by their conventional chemical formula written from left to right, they also encompass chemically identical substituents that would result from writing the structure from right to left, for example, -CH2O- is equivalent to -OCH2-.

[0028] Unless otherwise indicated, the term "alkyl" by itself or as part of another substituent means a straight (i.e., unbranched) or branched carbon chain (or carbons), or combinations thereof, which may be fully saturated, monounsaturated, or polyunsaturated, and may include monovalent, divalent, and polyvalent radicals. An alkyl group may contain a specified number of carbon atoms (e.g., C1-C 10Meaning one to ten carbons). Alkyl is an uncyclized chain. Examples of saturated hydrocarbon groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, methyl, homologues and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, etc. Unsaturated alkyl groups are alkyl groups having one or more double or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and higher homologues and isomers. Alkoxy is an alkyl group attached to the rest of the molecule via an oxygen linker (-O-). The alkyl moiety can be an alkenyl moiety. The alkyl moiety can be an alkynyl moiety. The alkyl moiety can be fully saturated. An alkenyl group may contain more than one double bond and / or one or more triple bonds in addition to one or more double bonds. An alkynyl group may contain more than one triple bond and / or one or more double bonds in addition to one or more triple bonds.

[0029] In embodiments, the term "cycloalkyl" means a monocyclic, bicyclic, or polycyclic cycloalkyl ring system. In embodiments, a monocyclic ring system is a cyclic hydrocarbon group containing 3 to 8 carbon atoms, wherein such groups may be saturated or unsaturated, but not aromatic. In embodiments, a cycloalkyl group is fully saturated. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. A bicyclic cycloalkyl ring system is a bridged monocyclic or fused bicyclic ring. In embodiments, a bridged monocyclic ring contains a monocyclic cycloalkyl ring in which two non-adjacent carbon atoms of the monocyclic ring are bridged by an alkylene group between one and three additional carbon atoms (i.e., (CH2) wIn one embodiment, the bicyclic cycloalkyl ring system comprises a phenyl, monocyclic cycloalkyl, monocyclic cycloalkenyl, monocyclic heterocyclyl or monocyclic heteroaryl fused monocyclic cycloalkyl ring. In one embodiment, the bicyclic cycloalkyl of the bridged or fused structure is attached to the parent molecular moiety through any carbon atom contained in the monocyclic cycloalkyl ring. In one embodiment, the cycloalkyl group is optionally substituted with one or two groups that are independently oxo or thio. In an embodiment, the fused bicyclic cycloalkyl is a 5 or 6-membered monocyclic cycloalkyl ring fused to a phenyl ring, a 5 or 6-membered monocyclic cycloalkyl, a 5 or 6-membered monocyclic heteroalkenyl, a 5 or 6-membered monocyclic heterocyclyl, or a 5 or 6-membered monocyclic heteroaryl, wherein the fused bicyclic cycloalkyl is optionally substituted with one or two groups that are independently oxo or thio. In an embodiment, the polycyclic cycloalkyl ring system is a monocyclic cycloalkyl ring (base ring) fused to any of the following: (i) one ring system selected from the group consisting of: bicyclic aromatic, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl; or (ii) two other ring systems independently selected from the group consisting of: phenyl, bicyclic aromatic, monocyclic or bicyclic heteroaryl, monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic cycloalkenyl, and monocyclic or bicyclic heterocyclyl. In an embodiment, the polycyclic cycloalkyl is attached to the parent molecular moiety through any carbon atom contained within the base ring. In an embodiment, the polycyclic cycloalkyl ring system is a monocyclic cycloalkyl ring (base ring) fused to any of the following: (i) one ring system selected from the group consisting of bicyclic aromatic groups, bicyclic heteroaryl groups, bicyclic cycloalkyl groups, bicyclic cycloalkenyl groups, and bicyclic heterocyclyl groups; or (ii) two other ring systems independently selected from the group consisting of phenyl groups, monocyclic heteroaryl groups, monocyclic cycloalkyl groups, monocyclic cycloalkenyl groups, and monocyclic heterocyclyl groups. Examples of polycyclic cycloalkyl groups include, but are not limited to, tetradecahydrophenanthrenyl groups, perhydrophenothiazin-1-yl groups, and perhydrophenoxazin-1-yl groups.

[0030] In an embodiment, cycloalkyl is a cycloalkenyl. The term "cycloalkenyl" is used according to its common general meaning. In an embodiment, a cycloalkenyl is a monocyclic, bicyclic or polycyclic cycloalkenyl ring system. In an embodiment, a monocyclic cycloalkenyl ring system is a cyclic hydrocarbon group containing 3 to 8 carbon atoms, wherein such a group is unsaturated (i.e., contains at least one annular carbon-carbon double bond), but is not aromatic. Examples of monocyclic cycloalkenyl ring systems include cyclopentenyl and cyclohexenyl. In an embodiment, a bicyclic cycloalkenyl ring is a bridged monocyclic or fused bicyclic ring. In an embodiment, a bridged monocyclic ring contains a monocyclic cycloalkenyl ring in which two non-adjacent carbon atoms of the monocyclic ring are connected by an alkylene bridge between one carbon atom and three other carbon atoms (i.e., of the form (CH2) wIn one embodiment, the fused bicyclic cycloalkenyl ring system contains a monocyclic cycloalkenyl ring fused to any one of a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. In one embodiment, the bridged or fused bicyclic cycloalkenyl is attached to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkenyl ring. In one embodiment, the cycloalkenyl group is optionally substituted with one or two groups that are independently oxo or thio. In embodiments, the polycyclic cycloalkenyl ring system contains a monocyclic cycloalkenyl ring (base ring) fused to either: (i) one ring system selected from the group consisting of bicyclic aromatic groups, bicyclic heteroaryl groups, bicyclic cycloalkyl groups, bicyclic cycloalkenyl groups, and bicyclic heterocyclyl groups; or (ii) two ring systems independently selected from the group consisting of phenyl groups, bicyclic aromatic groups, monocyclic or bicyclic heteroaryl groups, monocyclic or bicyclic cycloalkyl groups, monocyclic or bicyclic cycloalkenyl groups, and monocyclic or bicyclic heterocyclyl groups. In embodiments, the polycyclic cycloalkenyl group is attached to the parent molecular moiety through any carbon atom contained within the base ring. In embodiments, the polycyclic cycloalkenyl ring system contains a monocyclic cycloalkenyl ring (base ring) fused to either: (i) one ring system selected from the group consisting of bicyclic aromatic groups, bicyclic heteroaryl groups, bicyclic cycloalkyl groups, bicyclic cycloalkenyl groups, and bicyclic heterocyclyl groups; or (ii) two ring systems independently selected from the group consisting of phenyl groups, monocyclic heteroaryl groups, monocyclic cycloalkyl groups, monocyclic cycloalkenyl groups, and monocyclic heterocyclyl groups.

[0031] In an embodiment, heterocycloalkyl is a heterocyclic radical. As used herein, the term "heterocyclic radical" means a monocyclic, bicyclic or polycyclic heterocycle. The heterocyclic radical monocyclic heterocycle is a 3-, 4-, 5-, 6- or 7-membered ring containing at least one heteroatom independently selected from the group consisting of O, N and S, wherein the ring is saturated and or unsaturated, but not aromatic. The 3- or 4-membered ring contains 1 heteroatom selected from the group consisting of O, N and S. The 5-membered ring can contain zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S. The 6- or 7-membered ring contains zero, one or two double bonds and one, two or three heteroatoms selected from the group consisting of O, N and S. The heterocyclic radical monocyclic heterocycle is derived from any carbon atom or any nitrogen contained in the heterocyclic radical monocyclic heterocycle and is connected to the parent molecular moiety. Representative examples of heterocyclyl monocyclic heterocycles include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithiolanyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, diazolinyl, diazolidinyl, oxazolidinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiamorpholinyl, 1,1-dioxothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. Heterocyclyl bicyclic heterocycle is a monocyclic heterocycle fused to any one of phenyl, monocyclic cycloalkyl, monocyclic cycloalkenyl, monocyclic heterocycle or monocyclic heteroaryl.Heterocyclyl bicyclic heterocycle is connected to the parent molecular part by any carbon atom or any nitrogen atom contained in the monocyclic heterocyclic ring part of the bicyclic ring system.Representative examples of bicyclic heterocyclic radicals include but are not limited to 2,3-dihydrobenzofuran-2-yl, 2,3-dihydrobenzofuran-3-yl, dihydroindole-1-yl, dihydroindole-2-yl, dihydroindole-3-yl, 2,3-dihydrobenzothiophene-2-yl, decahydroquinolyl, decahydroisoquinolyl, octahydro-1H-indolyl and octahydrobenzofuranyl.In an embodiment, the heterocyclyl group is optionally substituted by one or two groups that are independently oxo or thio. In certain embodiments, the bicyclic heterocyclyl is a 5- or 6-membered monocyclic heterocyclyl ring fused to a benzene ring, a 5- or 6-membered monocyclic alkyl, a 5- or 6-membered monocyclic heteroalkenyl, a 5- or 6-membered monocyclic heterocyclyl, or a 5- or 6-membered monocyclic heteroaryl, wherein the bicyclic heterocyclyl is optionally substituted with one or two groups that are independently oxo or thio.A polycyclic heterocyclyl ring system is a monocyclic heterocyclyl ring (base ring) fused to either: (i) one ring system selected from the group consisting of bicyclic aromatic groups, bicyclic heteroaryl groups, bicyclic cycloalkyl groups, bicyclic cycloalkenyl groups, and bicyclic heterocyclyl groups; or (ii) two additional ring systems independently selected from the group consisting of phenyl groups, bicyclic aromatic groups, monocyclic or bicyclic heteroaryl groups, monocyclic or bicyclic cycloalkyl groups, monocyclic or bicyclic cycloalkenyl groups, and monocyclic or bicyclic heterocyclyl groups. The polycyclic heterocyclyl ring is attached to the parent molecular moiety through any carbon atom or nitrogen atom contained within the base ring. In an embodiment, the polycyclic heterocyclyl ring system is a monocyclic heterocyclyl ring (base ring) fused to either: (i) one ring system selected from the group consisting of bicyclic aromatic groups, bicyclic heteroaryl groups, bicyclic cycloalkyl groups, bicyclic cycloalkenyl groups, and bicyclic heterocyclyl groups; or (ii) two additional ring systems independently selected from the group consisting of phenyl groups, monocyclic heteroaryl groups, monocyclic cycloalkyl groups, monocyclic cycloalkenyl groups, and monocyclic heterocyclyl groups. Examples of polycyclic heterocyclyl groups include, but are not limited to, 10H-phenothiazin-10-yl, 9,10-dihydroacridin-9-yl, 9,10-dihydroacridin-10-yl, 10H-phenoxazin-10-yl, 10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl, 1,2,3,4-tetrahydropyrido[4,3-g]isoquinolin-2-yl, 12H-benzo[b]phenoxazin-12-yl, and dodecahydro-1H-carbazol-9-yl.

[0032] Unless otherwise stated, the term "alkylene" by itself or as part of another substituent means a divalent radical derived from an alkyl group, exemplified by, but not limited to, -CH2CH2CH2CH2-. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein. "Lower alkyl" or "lower alkylene" is a short-chain alkyl or alkylene group typically having eight or fewer carbon atoms. Unless otherwise stated, the term "alkenylene" by itself or as part of another substituent means a divalent radical derived from an alkene group.

[0033] Unless otherwise indicated, the term "heteroalkyl" by itself or in combination with another term means a stable straight or branched chain or combination thereof comprising at least one carbon atom and at least one heteroatom (e.g., O, N, S, Si, or P), and wherein the nitrogen and sulfur atoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. The heteroatom (e.g., O, N, S, Si, or P) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the rest of the molecule. A heteroalkyl group is an uncyclized chain. Examples include, but are not limited to, -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2, -S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, -O-CH3, -O-CH2-CH3, and -CN. Up to two or three heteroatoms can be consecutive, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. A heteroalkyl moiety can contain one heteroatom (e.g., O, N, S, Si, or P). A heteroalkyl moiety can contain two optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P). Unless otherwise stated, the term "heteroalkenyl" by itself or in combination with another term means a heteroalkyl group comprising at least one double bond. The heteroalkyl group may optionally include more than one double bond and / or one or more triple bonds in addition to one or more double bonds. Unless otherwise stated, the term "heteroalkynyl" by itself or in combination with another term means a heteroalkyl group comprising at least one triple bond. The heteroalkynyl group may optionally include more than one triple bond and / or one or more double bonds in addition to one or more triple bonds.

[0034] Similarly, unless otherwise indicated, the term "heteroalkylene" by itself or as part of another substituent means a divalent radical derived from a heteroalkyl group, exemplified by, but not limited to, -CH2-CH2-S-CH2-CH2- and -CH2-S-CH2-CH2-NH-CH2-. For heteroalkylene, heteroatoms may also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.). Still further, for alkylene and heteroalkylene linking groups, the direction in which the formula of the linking group is written does not imply the orientation of the linking group. For example, the formula -C(O)2R'- represents both -C(O)2R'- and -R'C(O)2-. As described above, heteroalkyl groups as used herein include those groups that are attached to the rest of the molecule through a heteroatom, such as -C(O)R', -C(O)NR', ​​-NR'R", -OR', -SR', and / or -S02R'. It should be understood that where "heteroalkyl" is recited after reciting a specific heteroalkyl group, such as -NR'R", the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl group is recited for added clarity. Therefore, the term "heteroalkyl" should not be interpreted herein to exclude specific heteroalkyl groups, such as -NR'R".

[0035] Unless otherwise indicated, the terms "cycloalkyl" and "heterocycloalkyl" by themselves or in combination with other terms refer to cyclic forms of "alkyl" and "heteroalkyl," respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom may occupy the position where the heterocycle is attached to the rest of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridinyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothiophen-2-yl, tetrahydrothiophen-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. "Cycloalkylene" and "heterocycloalkylene" by themselves or as part of another substituent mean a divalent radical derived from cycloalkyl and heterocycloalkyl, respectively.

[0036] Unless otherwise indicated, the term "halo" or "halogen" by itself or as part of another substituent means a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl" are intended to encompass monohaloalkyl and polyhaloalkyl. For example, the term "halo(C1-C4)alkyl" includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0037] Unless otherwise indicated, the term "acyl" means -C(O)R, where R is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0038] Unless otherwise indicated, the term "aryl" means a polyunsaturated aromatic hydrocarbon substituent, which can be a monocyclic ring or fused together (i.e., fused ring aryl) or covalently linked polycyclic rings (preferably 1 to 3 rings). Fused ring aryl refers to multiple rings fused together, wherein at least one of the fused rings is an aryl ring. The term "heteroaryl" refers to an aryl group (or ring) containing at least one heteroatom (such as N, O or S), wherein the nitrogen atom and the sulfur atom are optionally oxidized, and one or more nitrogen atoms are optionally quaternized. Therefore, the term "heteroaryl" includes fused ring heteroaryl (i.e., multiple rings fused together, wherein at least one of the fused rings is a heteroaryl ring). 5,6-fused ring heteroaryl refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Similarly, 6,6-fused ring heteroaryl refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And 6,5- fused ring heteroaryl refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring.Heteroaryl can be connected to the rest of the molecule through carbon or heteroatom.The limiting examples of aryl and heteroaryl include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidinyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothienyl, isoquinolyl, quinoxalinyl, quinolyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl , 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl and 6-quinolyl. Substituents for each of the above-noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. "Arylene" and "heteroarylene," by themselves or as part of another substituent, mean a divalent radical derived from aryl and heteroaryl, respectively. A heteroaryl substituent may be -O- attached to a ring heteroatom nitrogen.

[0039] Spirocycle is two or more rings in which adjacent rings are connected by a single atom. The single ring in the spirocycle can be the same or different. The single ring in the spirocycle can be substituted or unsubstituted and can have a substituent different from other single rings in the spirocycle set. The possible substituent of the single ring in the spirocycle is the possible substituent of the same ring when it is not a part of the spirocycle (for example, a substituent of a cycloalkyl ring or a heterocycloalkyl ring). The spirocycle can be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene or substituted or unsubstituted heterocycloalkylene, and the single ring in the spirocyclic group can be any ring in the immediately preceding list, comprising all rings with one type (for example, all rings of substituted heterocycloalkylene, wherein each ring can be the same or different substituted heterocycloalkylene). When referring to a spirocycle system, heterocycle spirocycle means that at least one ring is a heterocycle and wherein each ring can be a spirocycle of different rings. When referring to a spirocycle system, substituted spirocycle means that at least one ring is substituted and each substituent can optionally be different.

[0040] symbol Indicates the point of attachment of a chemical moiety to the rest of a molecule or chemical formula.

[0041] The term "oxo" as used herein means an oxygen double bonded to a carbon atom.

[0042] The term "alkylarylene" refers to an arylene moiety covalently linked to an alkylene moiety (also referred to herein as an alkylene linker). In an embodiment, the alkylarylene group has the formula:

[0043]

[0044] The alkylarylene moiety can be substituted (e.g., with a substituent) on the alkylene moiety or arylene linker (e.g., at carbon 2, 3, 4, or 6) with halogen, oxo, -N, -CF, -CCl, -CBr, -CI, -CN, -CHO, -OH, -NH, -COOH, -CONH, -NO, -SH, -SOCH, -SOH, -OSOH, -SONH, -NHNH, -ONH, -NHC(O)NHNH, substituted or unsubstituted C1-C5 alkyl, or substituted or unsubstituted 2 to 5 membered heteroalkyl. In an embodiment, the alkylarylene group is unsubstituted.

[0045] Each of the above terms (e.g., "alkyl," "heteroalkyl," "cycloalkyl," "heterocycloalkyl," "aryl," and "heteroaryl") includes substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.

[0046] Substituents for alkyl and heteroalkyl groups (including those groups commonly referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, -OR', =O, =NR', =N-OR', -NR'R", -SR', -halogen, -SiR'R"R"', -OC(O)R', -C(O)R', -CO2R', -CONR'R" , -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R"')=NR"", -NR-C(NR'R" )=NR”', -S(O)R', -S(O)2R', -S(O)2NR'R”, -NRSO2R', -NR'NR"R"', -ONR'R", -NR'C(O)NR"NR"'R"", - CN, -NO2, -NR'SO2R", -NR'C(O)R", -NR'C(O)-OR", -NR'OR", the numerical range is zero to (2m'+1), where m' is the total number of carbon atoms in such radicals. R, R', R", R'' and R"" each preferably independently represent hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., with 1-3 halogens), substituted or unsubstituted aryl, ... When the compounds described herein contain more than one R group, each of the R groups is independently selected, for example, as each R' group, R" group, R"' group and R"" group is independently selected when more than one of these groups is present. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-membered, 5-membered, 6-membered or 7-membered ring. For example, -NR'R" includes but is not limited to 1-pyrrolidinyl and 4-morpholinyl. Based on the above discussion of substituents, those skilled in the art will understand that the term "alkyl" is intended to include groups containing carbon atoms combined with groups other than hydrogen groups, such as haloalkyl (e.g., -CF3 and -CH2CF3) and acyl (e.g., -C(O)CH3, -C(O)CF3, -C(O)CH2OCH3, etc.).

[0047] Similar to the substituents described for alkyl, substituents for aryl and heteroaryl groups are varied and are selected from, for example: -OR', -NR'R", -SR', -halogen, -SiR'R"R"', -OC(O)R', -C(O)R', -C02R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R"')=NR"", -NR-C(NR'R")=NR"', -S(O)R', -S(O)2R', -S(O)2NR'R", -NRSO2R', -NR'NR"R"', -ONR'R", -NR'C(O)NR"NR"'R"', -CN, -NO2, -R', - N3, -CH(Ph)2, fluoro(C1-C4)alkoxy and fluoro(C1-C4)alkyl, -NR'SO2R", -NR'C(O)R", -NR'C(O)-OR", -NR'OR", and wherein R', R", R"' and R"" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When the compounds described herein contain more than one R group, for example, each of the R groups is independently selected as each R' group, R" group, R"' group, and R"" group is independently selected when more than one of these groups is present.

[0048] The substituent of a ring (e.g., cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylidene or heteroarylidene) can be depicted as a substituent on a specific atom of the ring rather than on the ring (commonly referred to as a floating substituent). In this case, the substituent can be connected to any ring atom in the ring atoms (following chemical valence rules), and in the case of a fused ring or spirocycle, the substituent depicted as being associated with a member of the fused ring or spirocycle (floating substituent on a monocycle) can be a substituent on any one of the fused ring or spirocycle (floating substituent on multiple rings). When the substituent is connected to the ring rather than a specific atom (floating substituent) and the subscript of the substituent is an integer greater than one, multiple substituents can be located on the same atom, the same ring, different atoms, different fused rings, different spirocycles, and each substituent can be optionally different. In the case where the point of attachment of the ring to the rest of the molecule is not limited to a single atom (floating substituent), the point of attachment can be any atom of the ring, and in the case of a fused ring or spirocycle, it can be any atom of any one of the fused ring or spirocycle (following chemical valence rules). Where a ring, fused ring, or spiro ring contains one or more ring heteroatoms and the ring, fused ring, or spiro ring is shown as having a further floating substituent (including but not limited to a point of attachment to the rest of the molecule), the floating substituent may be bonded to the heteroatom. Where a ring heteroatom is shown as bonded to one or more hydrogens in a structure or formula having a floating substituent (e.g., a ring nitrogen having two bonds to ring atoms and a third bond to a hydrogen), when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen while respecting chemical valence rules.

[0049] Two or more substituents can be optionally connected to form aryl, heteroaryl, cycloalkyl or heterocycloalkyl. It is found that this type of so-called ring-forming substituent is usually (but not necessarily) attached to the cyclic base structure. In one embodiment, the ring-forming substituent is connected to the adjacent members of the base structure. For example, two ring-forming substituents connected to the adjacent members of the cyclic base structure produce a condensed ring structure. In another embodiment, the ring-forming substituent is connected to the single member of the base structure. For example, two ring-forming substituents connected to the single member of the cyclic base structure produce a spirocyclic structure. In another embodiment, the ring-forming substituent is connected to the non-adjacent members of the base structure.

[0050] Two substituents on adjacent atoms of an aryl or heteroaryl ring may optionally form a ring of the formula -TC(O)-(CRR') q -U-, wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer from 0 to 3. Alternatively, two substituents on adjacent atoms of the aromatic or heteroaromatic ring may be optionally replaced by a substituent of the formula -A-(CH2) r-(CRR')-, -O-, -NR-, -S-, -S(O)-, -S(O)2-, -S(O)2NR'-, or a single bond, and r is an integer from 1 to 4. One of the single bonds of the new ring thus formed may optionally be replaced by a double bond. Alternatively, two substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced by a substituent of the formula -(CRR')- s -X'-(C”R”R”') d -, wherein s and d are independently integers from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -S(O)2-, or -S(O)2NR'-. The substituents R, R', R" and R'" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

[0051] As used herein, the term "heteroatom" or "ring heteroatom" is intended to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).

[0052] As used herein, a "substituent" means a group selected from the following moieties:

[0053] (A) Oxo, halogen, –CF3, –CCl3, –CBr3, –CI3, –CHF2, –CHCl2, –CHBr2, –CHI2, -CH2F, –CH2Cl, –CH2Br, –CH2I, -CN, -N3, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, –OCF3, –OCCl3, –OC Br3, –OCI3, –OCHF2, –OCHCl2, –OCHBr2, –OCHI2, –OCH2F, –OCH2Cl, –OCH2Br, –OCHI, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C 10 Aryl, C10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and

[0054] (B) an alkyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group substituted with at least one substituent selected from the group consisting of:

[0055] (i) Oxo, halogen, –CF3, –CCl3, –CBr3, –CI3, –CHF2, –CHCl2, –CHBr2, –CHI2, -CH2F, –CH2Cl, –CH2Br, –CH2I, -CN, -N3, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, –OCF3, –OCCl3, –OC Br3, –OCI3, –OCHF2, –OCHCl2, –OCHBr2, –OCHI2, –OCH2F, –OCH2Cl, –OCH2Br, –OCHI, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C 10 Aryl, C 10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and

[0056] (ii) an alkyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group substituted with at least one substituent selected from the group consisting of:

[0057] (a) Oxo, halogen, –CF3, –CCl3, –CBr3, –CI3, –CHF2, –CHCl2, –CHBr2, –CHI2, -CH2F, –CH2Cl, –CH2Br, –CH2I, -CN, -N3, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, –OCF3, –OCCl3, –OC Br3, –OCI3, –OCHF2, –OCHCl2, –OCHBr2, –OCHI2, –OCH2F, –OCH2Cl, –OCH2Br, –OCHI, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C 10 Aryl, C 10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and

[0058] (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl substituted with at least one substituent selected from the group consisting of oxo, halogen, –CF3, –CCl3, –CBr3, –CI3, –CHF2, –CHCl2, –CHBr2, –CHI2, –CH2F, –CH2Cl, –CH2Br, –CH2I, –CN, –N3, –OH, –NH2, –COOH, –CONH2, –NO2, –SH, –SCH3, –SO3H, –SO4H, –SO2NH2, –NHNH2, –ONH2, –NHC(O)NHNH2, –NHC(O)NH2, –NHSO2H, –NHC(O)H, –NHC(O)OH, –N HOH, –OCF3, –OCCl3, –OCBr3, –OCI3, –OCHF2, –OCHCl2, –OCHBr2, –OCHI2, –OCH2F, –OCH2Cl, –OCH2Br, –OCHI, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C 10 Aryl, C 10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl).

[0059] As used herein, "size-limited substituent" or "size-limited substituent group" means a group selected from all substituents described above for "substituent", wherein each substituted or unsubstituted alkyl group is a substituted or unsubstituted C1-C 20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 20-membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3- to 8-membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C 10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5- to 10-membered heteroaryl.

[0060] As used herein, "lower substituent" or "lower substituent group" means a group selected from all substituents described above for "substituent", wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2-membered to 8-membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3-membered to 7-membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C 10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5- to 9-membered heteroaryl.

[0061] In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and / or substituted or unsubstituted heteroarylene) is unsubstituted (e.g., unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted alkylene, unsubstituted heteroalkylene, unsubstituted cycloalkylene, unsubstituted heterocycloalkylene, unsubstituted arylene, and / or unsubstituted heteroarylene, respectively). In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and / or substituted or unsubstituted heteroarylene) is substituted (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene, respectively).

[0062] In an embodiment, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene and / or substituted heteroarylene) is substituted with at least one substituent, wherein if the substituted moiety is substituted with multiple substituents, each substituent may optionally be different. In an embodiment, if the substituted moiety is substituted with multiple substituents, each substituent is different.

[0063] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one size-restricted substituent, wherein if the substituted moiety is substituted with multiple size-restricted substituents, each size-restricted substituent may optionally be different. In embodiments, if the substituted moiety is substituted with multiple size-restricted substituent groups, each size-restricted substituent group is different.

[0064] In an embodiment, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene and / or substituted heteroarylene) is substituted with at least one low substituent, wherein if the substituted moiety is substituted with multiple low substituents, each low substituent may optionally be different. In an embodiment, if the substituted moiety is substituted with multiple low substituent groups, each low substituent group is different.

[0065] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted moiety is substituted with multiple groups selected from substituents, size-restricted substituents, and lower substituents; each substituent, size-restricted substituent, and / or lower substituent may optionally be different. In embodiments, if the substituted moiety is substituted with multiple groups selected from substituents, size-restricted substituents, and lower carbon number substituents, each substituent, size-restricted substituent, and / or lower carbon number substituent is different.

[0066] In embodiments of compounds herein, each substituted or unsubstituted alkyl group can be substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted C1-C 20 alkyl, each substituted or unsubstituted heteroalkyl is substituted (e.g., substituted by a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted 2- to 20-membered heteroalkyl, each substituted or unsubstituted cycloalkyl is substituted (e.g., substituted by a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is substituted (e.g., substituted by a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted 3- to 8-membered heterocycloalkyl, each substituted or unsubstituted aryl is substituted (e.g., substituted by a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted C6-C 10 Aryl, and / or each substituted or unsubstituted heteroaryl is a substituted (e.g., substituted with a substituent, a substituent with limited size, or a lower substituent) or unsubstituted 5- to 10-membered heteroaryl. In the embodiments herein, each substituted or unsubstituted alkylene is a substituted (e.g., substituted with a substituent, a substituent with limited size, or a lower substituent) or unsubstituted C1-C 20 alkylene, each substituted or unsubstituted heteroalkylene is substituted (e.g., substituted by a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted 2- to 20-membered heteroalkylene, each substituted or unsubstituted cycloalkylene is substituted (e.g., substituted by a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted C3-C8 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is substituted (e.g., substituted by a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted 3- to 8-membered heterocycloalkylene, each substituted or unsubstituted arylene is substituted (e.g., substituted by a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted C6-C 10 The arylene group, and / or each substituted or unsubstituted heteroarylene group is a substituted (eg, substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted 5- to 10-membered heteroarylene group.

[0067] In embodiments, each substituted or unsubstituted alkyl group is a substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted C1-C8 alkyl group, each substituted or unsubstituted heteroalkyl group is a substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted 2- to 8-membered heteroalkyl group, each substituted or unsubstituted cycloalkyl group is a substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted C3-C7 cycloalkyl group, each substituted or unsubstituted heterocycloalkyl group is a substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted 3- to 7-membered heterocycloalkyl group, each substituted or unsubstituted aryl group is a substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted C6-C 10 Aryl, and / or each substituted or unsubstituted heteroaryl is a substituted (eg, substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted 5- to 9-membered heteroaryl. In embodiments, each substituted or unsubstituted alkylene group is a substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted C1-C8 alkylene group, each substituted or unsubstituted heteroalkylene group is a substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted 2- to 8-membered heteroalkylene group, each substituted or unsubstituted cycloalkylene group is a substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted C3-C7 cycloalkylene group, each substituted or unsubstituted heterocycloalkylene group is a substituted or unsubstituted 3- to 7-membered heterocycloalkylene group, each substituted or unsubstituted arylene group is a substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted C6-C 10 Arylene, and / or each substituted or unsubstituted heteroarylene is a substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted 5- to 9-membered heteroarylene. In embodiments, the compound is a chemical species described in the Examples section, Figures, or Tables below.

[0068] Certain compounds provided herein have asymmetric carbon atoms (optical or chiral centers) or double bonds; in terms of absolute stereochemistry, (R)- or (S)-, or (D)- or (L)-enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomeric forms of amino acids, and individual isomers are encompassed within the scope of this disclosure. Compounds provided herein do not include those known in the art that are too unstable to synthesize and / or separate. Compounds provided herein include those in racemic and optically pure forms. Optically active (R)- and (S)- or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other geometric asymmetric centers, and unless otherwise indicated, it is desirable that the compounds include both E and Z geometric isomers.

[0069] As used herein, the term "isomers" refers to compounds that have the same number and kind of atoms, and therefore the same molecular weight, but differ in the structural arrangement or configuration of the atoms.

[0070] As used herein, the term "tautomer" refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another.

[0071] It will be apparent to those skilled in the art that certain compounds provided herein may exist in tautomeric forms, and all such tautomeric forms of the compounds are within the scope of the present disclosure.

[0072] When the compounds disclosed herein have at least one chiral center, they can exist as individual enantiomers and diastereomers or as mixtures of such isomers, including racemates. The separation of individual isomers or the selective synthesis of individual isomers is achieved by applying various methods known to practitioners in the art. Unless otherwise indicated, all such isomers and mixtures thereof are included within the scope of the compounds disclosed herein. Unless otherwise indicated, the structures depicted herein are also intended to include all stereochemical forms of the structure; that is, the (R) and (S) configurations of each asymmetric center. Therefore, it is generally recognized by those skilled in the art that single stereochemical isomers of stable compounds of the present invention and mixtures of enantiomers and diastereomers are within the scope of the present disclosure.

[0073] Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, in addition to the replacement of hydrogen by deuterium or tritium, or the replacement of fluorine by 18 F is replaced or carbon is 13 C- or 14Compounds having the present structures other than C-enriched carbon substitutions are within the scope of this disclosure.

[0074] The compounds provided herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, a compound may be prepared with, for example, tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds provided herein, whether radioactive or not, are encompassed by the present disclosure.

[0075] It should be noted that throughout the application, alternatives are written as Markush groups, e.g., in each amino acid position containing more than one possible amino acid. It is specifically contemplated that each member of a Markush group should be considered individually, thereby comprising another embodiment, and that a Markush group should not be understood as a single unit.

[0076] "Similar" or "analog" is used according to its ordinary, common meaning in chemistry and biology and refers to a compound that is structurally similar to another compound (i.e., the so-called "reference" compound) but differs in composition, for example, in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or in the replacement of one functional group by another functional group, or in the absolute stereochemistry of one or more chiral centers of the reference compound. Thus, an analog is a compound that is similar or equivalent in function and appearance to a reference compound, but not in structure or origin.

[0077] As used herein, the term "a" or "an" means one or more. Additionally, as used herein, the phrase "substituted with [n]" means that the specified group may be substituted with one or more of any or all of the named substituents. For example, when a group such as an alkyl or heteroaryl group is "substituted with an unsubstituted C1-C 20 When "substituted by alkyl or unsubstituted 2- to 20-membered heteroalkyl", the group may contain one or more unsubstituted C1-C 20 alkyl, and / or one or more unsubstituted 2- to 20-membered heteroalkyl groups.

[0078] When a moiety is substituted with an R substituent, the group may be referred to as "R-substituted". When a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different. When a specific R group is present in the description of a chemical genus such as Formula (I), Roman decimal notation may be used to distinguish each occurrence of that specific R group. For example, when multiple R 13 When a substituent is present, each R 13 Substituents can be divided into R13.1 、R 13.2 、R 13.3 、R 13.4 etc., where R 13.1 、R 13.2 、R 13.3 、R 13.4 Each of the above in R 13 and optionally different. As used herein, the term "a / an" means one or more. In addition, as used herein, the phrase "substituted with a / an" means that the specified group may be substituted with one or more of any or all of the named substituents. For example, when a group such as an alkyl or heteroaryl group is "substituted with an unsubstituted C1-C 20 When "substituted by alkyl or unsubstituted 2- to 20-membered heteroalkyl", the group may contain one or more unsubstituted C1-C 20 alkyl, and / or one or more unsubstituted 2- to 20-membered heteroalkyl groups.

[0079] The descriptions of the compounds provided herein are limited by the principles of chemical bonding known to those skilled in the art. Thus, when a group may be substituted by one or more of a plurality of substituents, such substitutions are selected so as to conform to the principles of chemical bonding and to yield compounds that are not inherently unstable and / or will be known to those of ordinary skill in the art as being unstable under environmental conditions such as aqueous, neutral, and several known physiological conditions. For example, heterocycloalkyl or heteroaryl groups are attached to the rest of the molecule via ring heteroatoms according to the principles of chemical bonding known to those skilled in the art, thereby avoiding inherently unstable compounds.

[0080] The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness and properties of a compound and is not biologically or otherwise undesirable for use in medicine. In many cases, the compounds herein are capable of forming acid and / or base salts due to the presence of amino and / or carboxyl groups or groups similar thereto. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; ammonium, potassium, sodium, calcium, and magnesium salts are particularly preferred. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. Many such salts are known in the art, as described in WO 87 / 05297 to Johnston et al., published September 11, 1987 (incorporated herein by reference in its entirety).

[0081] "Contacting" is used according to its ordinary meaning and refers to the process of allowing at least two different species (e.g., compounds, biomolecules, or cells) to come into close enough proximity to react, interact, or physically touch. For example, contacting includes the process of allowing a compound to come into close enough proximity to a cell to bind to a cell surface receptor.

[0082] As used herein, "contacting a cell" refers to a situation in which a compound or other composition of matter is in direct contact with a cell or is sufficiently close to induce a desired biological effect in the cell.

[0083] As defined herein, the terms "inhibition," "inhibit," "inhibiting," and the like mean to adversely affect (e.g., reduce) an activity or function relative to the activity or function in the absence of the inhibitor. In embodiments, inhibition means to adversely affect (e.g., reduce) the concentration or level of a biomolecule, such as a protein or mRNA, relative to the concentration or level of the biomolecule in the absence of the inhibitor. For example, inhibition includes reducing the level of mRNA expression in a cell. In embodiments, inhibition refers to a reduction in the activity of a specific biomolecule target, such as a protein target or an mRNA target. Thus, inhibition includes at least partially, partially, or completely blocking a stimulus; reducing, preventing, or delaying activation; or inactivating, desensitizing, or downregulating a signal transduction or enzyme activity or the amount of a biomolecule. In embodiments, inhibition refers to a reduction in the activity of a target biomolecule resulting from a direct interaction (e.g., binding of the inhibitor to a target protein). In embodiments, inhibition refers to a reduction in the activity of a target biomolecule resulting from an indirect interaction (e.g., binding of the inhibitor to a protein that activates the target protein, thereby preventing activation of the target protein).

[0084] The term "inhibitor" also refers to a compound, composition, or substance that can detectably reduce the expression or activity of a given gene or protein. For example, an inhibitor can reduce expression or activity by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to a control in the absence of the inhibitor. Inhibitors include, for example, synthetic or biological molecules, such as oligonucleotides.

[0085] As used herein, the terms "expression" and "gene expression" refer to the steps involved in translating nucleic acids into proteins, including mRNA expression and protein expression. Expression can be detected using conventional techniques for detecting nucleic acids or proteins (e.g., PCR, ELISA, Southern blotting, Western blotting, flow cytometry, FISH, immunofluorescence, immunohistochemistry).

[0086] An "effective amount" is an amount of a compound sufficient to achieve its stated purpose relative to the absence of the compound (e.g., to achieve the effect of its administration, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition). As used herein, an "activity-reducing amount" refers to the amount of an antagonist required to reduce the activity of an enzyme relative to the absence of the antagonist. As used herein, a "function-disrupting amount" refers to the amount of an antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist.

[0087] As used herein, the term "in vivo" refers to a process that occurs within the body of a subject.

[0088] As used herein, the term "subject" refers to a human or non-human animal selected for treatment or therapy. In an embodiment, the subject is a human.

[0089] As used herein, the term "ex vivo" refers to a process that occurs in vitro in isolated tissues or cells, wherein the treated tissues or cells comprise primary cells. As is known in the art, any medium used in the process may be aqueous and non-toxic so as not to render the tissues or cells inert. In an embodiment, the ex vivo process is performed in vitro using primary cells.

[0090] The term "administering" means providing an agent or composition to a subject and includes administration by a medical professional and self-administration.

[0091] The term "treating" means the application of one or more specific procedures for improving at least one indicator or disease or condition. In an embodiment, the specific procedure is the administration of one or more pharmaceutical agents.

[0092] The term "modulate" is used herein in its ordinary sense as understood by those of ordinary skill in the art, and thus refers to the act of changing or altering one or more properties. For example, in the context of the effect of a modulator on a target molecule, modulating means altering by increasing or decreasing a property or function of the target molecule or the amount of the target molecule. A modulator of a disease reduces a symptom, cause, or characteristic of the target disease.

[0093] The term "nucleic acid" means a compound comprising at least two nucleotide monomers covalently linked together. Nucleic acids include polynucleotides and oligonucleotides, including double-stranded oligonucleotides and single-stranded oligonucleotides, and modified forms thereof.

[0094] The term "polynucleotide" means a nucleic acid of a longer length, for example, 200, 300, 500, 1000, 2000, 3000, 5000, 7000 or 10,000 nucleotides in length. Non-limiting examples of polynucleotides include genes, gene fragments, exons, introns, intergenic DNA (including but not limited to heterochromatic DNA), messenger RNA (mRNA), long non-coding RNA, transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of sequences and isolated RNA of sequences. The polynucleotides that can be used in the methods of the present disclosure can include natural nucleic acid sequences and variants thereof, artificial nucleic acid sequences or combinations of such sequences.

[0095] The term "oligonucleotide" means a nucleic acid having a shorter length, for example, less than 100 nucleotides in length. Oligonucleotides can be single-stranded or double-stranded. Oligonucleotides can include naturally occurring ribonucleotides, naturally occurring deoxyribonucleotides and / or naturally occurring ends, sugars, core bases and / or internucleotide bonds with one or more modifications. Non-limiting examples of oligonucleotides include double-stranded oligonucleotides, single-stranded oligonucleotides, antisense oligonucleotides, small interfering RNA (siRNA), microRNA mimics, short hairpin RNA (shRNA), single-stranded small interfering RNA (ssRNAi), RNaseH oligonucleotides, anti-microRNA oligonucleotides, space blocking oligonucleotides, exon skipping oligonucleotides, CRISPR guide RNA and aptamers.

[0096] The term "single-stranded oligonucleotide" means an oligonucleotide that does not hybridize to a complementary strand. Non-limiting examples of single-stranded oligonucleotides include single-stranded small interfering RNA (ssRNAi), RNaseH oligonucleotides (oligonucleotides chemically modified to trigger RNaseH-mediated degradation of target RNA), anti-microRNA oligonucleotides (oligonucleotides complementary to microRNA), steric blocking oligonucleotides (oligonucleotides that interfere with target RNA activity without degrading target RNA), exon skipping oligonucleotides (oligonucleotides that hybridize to exon annealing sites and alter splicing), CRISPR guide RNAs, and aptamers.

[0097] The term "hybridization" refers to the annealing of one nucleic acid to another nucleic acid based on nucleobase sequence complementarity. In an embodiment, the antisense strand hybridizes to the sense strand. In an embodiment, the antisense strand hybridizes to a target mRNA sequence.

[0098] The term "complementary" means that the nucleobases have the ability to pair non-covalently via hydrogen bonding.

[0099] The term "fully complementary" means that each nucleobase of a first nucleic acid is complementary to each nucleobase of a second nucleic acid. In an embodiment, the antisense strand is fully complementary to its target mRNA. In an embodiment, the sense and antisense strands of a double-stranded oligonucleotide are fully complementary over their entire length. In an embodiment, the sense and antisense strands of a double-stranded oligonucleotide are fully complementary over the entire length of the double-stranded region of the siRNA, and one or both ends of either strand contain single-stranded nucleotides.

[0100] The term "nucleoside" means a monomer of a nucleobase and a pentofuranoside sugar (e.g., ribose or deoxyribose). Nucleosides can be modified on the nucleobase and / or sugar. In an embodiment, the nucleoside is a deoxyribonucleoside. In an embodiment, the nucleoside is a ribonucleoside.

[0101] The term "nucleotide" means a nucleoside covalently linked to a phosphate group at the 5'-carbon of a pentofuranosyl sugar. Nucleotides can be modified at one or more nucleobases, sugars, or phosphate groups. Nucleotides can have ligands attached directly or via a linker. In an embodiment, the nucleotide is a deoxyribonucleotide. In an embodiment, the nucleotide is a ribonucleotide.

[0102] The term "nucleobase" means the heterocyclic base portion of a nucleoside or nucleotide. Non-limiting examples of nucleobases include cytosine or a derivative thereof (e.g., a cytosine analog), guanine or a derivative thereof (e.g., a guanine analog), adenine or a derivative thereof (e.g., an adenine analog), thymine or a derivative thereof (e.g., a thymine analog), uracil or a derivative thereof (e.g., a uracil analog), hypoxanthine or a derivative thereof (e.g., a hypoxanthine analog), xanthine or a derivative thereof (e.g., a xanthine analog), 7-methylguanine or a derivative thereof (e.g., a 7-methylguanine analog), deazaadenine or a derivative thereof (e.g., a deazaadenine analog), deazaguanine or a derivative thereof (e.g., deazaguanine), deazahypoxanthine or a derivative thereof, 5,6-dihydrouracil or a derivative thereof (e.g., a 5,6-dihydrouracil analog), 5-methylcytosine or a derivative thereof (e.g., a 5-methylcytosine analog), or a 5-hydroxymethylcytosine or a derivative thereof (e.g., a 5-hydroxymethylcytosine analog) moiety. In embodiments, the nucleobase is adenine, guanine, hypoxanthine, xanthine, theobromine, caffeine, uric acid, or isoguanine, which may be optionally substituted or modified. In embodiments, the nucleobase is It may be optionally substituted or modified.

[0103] The term "modified nucleotides" means nucleotides that have one or more modifications relative to naturally occurring nucleotides. Modifications can be present in the internucleoside linkages, core bases, and / or sugar moieties of the nucleotide. Due to desired properties, such as, for example, enhanced cellular uptake, enhanced affinity for other oligonucleotides or nucleic acid targets, increased stability in the presence of nucleases, and / or reduced immunostimulation, modified nucleotides can be selected relative to the unmodified form. Modified nucleotides can have modified sugar moieties and unmodified phosphate groups. Modified nucleotides can have unmodified sugar moieties and modified phosphate groups. Modified nucleotides can have modified sugar moieties and unmodified core bases. Modified nucleotides can have modified sugar moieties and modified phosphate groups. Nucleic acids, polynucleotides, and oligonucleotides can contain one or more modified nucleotides.

[0104] As used herein, the term "complement" refers to a nucleotide (e.g., RNA or DNA) or a nucleotide sequence that can base pair with a complementary nucleotide or nucleotide sequence. As described herein and as known in the art, the complementary (matching) nucleotide of adenosine is thymidine, and the complementary (matching) nucleotide of guanine is cytosine. Therefore, the complement can include a nucleotide sequence that base pairs with the corresponding complementary nucleotide of the second nucleic acid sequence. The nucleotides of the complement can partially or completely match the nucleotides of the second nucleic acid sequence. When the nucleotides of the complement fully match each nucleotide of the second nucleic acid sequence, the complement forms a base pair with each nucleotide of the second nucleic acid sequence. When the nucleotides of the complement partially match the nucleotides of the second nucleic acid sequence, only some nucleotides of the complement form a base pair with the nucleotides of the second nucleic acid sequence. The example of a complementary sequence includes coding and non-coding sequences, wherein the non-coding sequence contains the complementary nucleotides of the coding sequence, thereby forming the complement of the coding sequence. Another example of a complementary sequence is sense and antisense sequences, wherein the sense sequence contains the complementary nucleotides of the antisense sequence, thereby forming the complement of the antisense sequence.

[0105] As described herein, the complementarity of sequences can be partial, in which only some nucleic acids match according to base pairing, or complete, in which all nucleic acids match according to base pairing. Thus, two sequences that are complementary to each other can have a specified percentage of nucleotides that participate in core base pairing (i.e., about 60% complementarity over a specified region, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more complementarity).

[0106] "Hybridization" should mean the annealing of a single-stranded nucleic acid (such as a primer) and another nucleic acid based on the known principle of sequence complementarity. In one embodiment, another nucleic acid is a single-stranded nucleic acid. The tendency of hybridization between nucleic acids depends on the temperature and ionic strength of its microu, the length of nucleic acid and the degree of complementarity. The impact of these parameters on hybridization is described in, for example, Sambrook J, Fritsch EF, Maniatis T, "Molecular cloning: laboratory manual", Cold Spring Harbor Laboratory Press, New York (1989). As used herein, the hybridization of primers or DNA extension products can be extended by producing a phosphodiester bond with available nucleotides or nucleotide analogs that can form a phosphodiester bond therewith.

[0107] The terms "same" or "percent identity" in the context of two or more nucleic acid or polypeptide sequences refer to two or more sequences or subsequences that are identical or have a specified percentage of amino acid residues or identical nucleotides (i.e., at least 60% identity, or at least 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 200%, 201 %. The term "identity" refers to a sequence identity percentage that is a sequence that has a sequence identity of at least 1 to 2.5, or more preferably ... Appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared, can be determined by known methods.

[0108] The term "dystrophin pre-mRNA" refers to the dystrophin transcript containing exons 1 to 79 and flanking introns. Human dystrophin pre-mRNA is encoded by the gene defined by the NCBI reference sequence NG_012232.1, created on July 17, 2019.

[0109] The term "suitable for exon skipping" means one or more mutations in the dystrophin gene that cause the reading frame to be out of frame, thereby destroying the translation of the pre-mRNA, resulting in the inability to produce functional or semi-functional dystrophin. Exon skipping of the dystrophin pre-mRNA containing such mutations is induced to restore the reading frame, allowing the production of functional or semi-functional dystrophin. Whether a subject has a mutation suitable for exon skipping can be determined by standard diagnostic tests for Duchenne muscular dystrophy (see, for example, Bello et al., 2016, Neurology, 87: 401-409).

[0110] The term "annealing site" means the region of the dystrophin pre-mRNA that is complementary to the nucleobase sequence of the oligonucleotide. The annealing site is described by the symbol S#A / D (+ / -x:+ / -y), where "S" represents the species, "#" represents the number of exons, "A" indicates the splice acceptor site, "D" indicates the splice donor site, "x" and "y" indicate the annealing coordinates, "+" indicates the exon nucleotide position, and "-" indicates the intron nucleotide position. As an example of an annealing site that includes a splice acceptor site, A(-3+22) indicates the last three nucleotides of the intron before the specified exon and the first 22 bases of the specified exon. As an example of an annealing site that includes a splice donor site, D(+5-20) indicates the last five nucleotides of the specified exon and the first 20 nucleotides of the intron after the specified exon. For example, the annealing site H51A (+66+95) indicates a site between nucleotides 66 and 95 from exon 51 of the human dystrophin pre-mRNA. Information on the location of introns and exons within the dystrophin gene can be found in the Ensembl database, listed under gene record ENSG00000198947.

[0111] The term "intron" refers to the nucleotide sequence flanking a gene coding sequence. Introns have two different nucleotides at either end. At the 5' end, the DNA nucleotides are "GT" (GU in pre-mRNA), and at the 3' end, they are "AG". These nucleotides are part of the splice site. Each intron contains three sites necessary for splicing to occur: a splice donor site, a splice acceptor site, and a splice branch point.

[0112] The term "exon" means the coding sequence of a gene.

[0113] The term "splice donor site" refers to the splice site at the 5' end of an intron, which has the sequence "NGT" in DNA or the sequence "NGU" in pre-mRNA (where "N" is A, C, G, T, or U), where splicing occurs before the "G".

[0114] The term "splice acceptor site" means the splice site at the 3' end of an intron, which has the sequence "NAGNN" (where "N" is A, C, G, T, or U), where splicing occurs after the "G." The "AG" sequence indicates the end of an intron.

[0115] The term "exonic splicing enhancer" or "ESE" refers to a non-splicing site to which SR proteins bind to promote exonic splice site recognition.

[0116] The term "splice branch point" refers to the nucleotides of an intron that participate in splicing by promoting the formation of a branched RNA lariat.

[0117] Compound

[0118] In one aspect, the compound has formula (IV):

[0119] wherein t is an integer from 1 to 5.

[0120] In an embodiment, t is 1. In an embodiment, t is 2. In an embodiment, t is 3. In an embodiment, t is 4. In an embodiment, t is 5.

[0121] A is a single-stranded oligonucleotide having a nucleobase sequence complementary to dystrophin pre-mRNA.

[0122] L 3 and L 4 are independently a bond, -N(R 23 )-, -O-, -S-, -C(O)-, -N(R 23 )C(O)-、-C(O)N(R 24 )-、-N(R 23 )C(O)N(R 24 )-、-C(O)O-、-OC(O)-、-N(R 23 )C(O)O-、-OC(O)N(R 24 )-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-、-OP(S)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N-、-OP(S)(NR 23 R 24 )-N-、-OP(O)(NR 23 R 24 )-O-、-OP(S)(NR 23 R 24 )-O-、-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R 24 )-O-、-P(S)(NR 23 R 24 )-O-, -SS-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene. Each R 23 、R24 and R 25 are independently hydrogen or unsubstituted C1-C 10 alkyl.

[0123] L 5 Yes-L 5A -L 5B -L 5C -L 5D -L 5E - and L 6 Yes-L 6A -L 6B -L 6C -L 6D -L 6E -.L 5A , L 5B , L 5C , L 5D , L 5E , L 6A , L 6B , L 6C , L 6D and L 6E and -S- are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0124] R 1 and R 2 are independently unsubstituted C1-C 25 Alkyl, where R 1 and R 2 At least one of them is unsubstituted C9-C 19 In an embodiment, R 1 and R 2 are independently unsubstituted C1-C 20 Alkyl, where R 1 and R 2 At least one of them is unsubstituted C9-C 19 alkyl.

[0125] R 3is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0126] In an embodiment, an L 3 Attached at the 3' end to the 3' carbon of a single-stranded oligonucleotide.

[0127] In an embodiment, an L 3 Attached to the 3' nitrogen of the single-stranded oligonucleotide (eg, the 3' nitrogen of the morpholino moiety) at the 3' end of the single-stranded oligonucleotide.

[0128] In an embodiment, an L 3 Attached at the 5' end to the 5' carbon of a single-stranded oligonucleotide.

[0129] In an embodiment, an L 3 Attached at the 5' end to the 6' carbon of a single-stranded oligonucleotide (eg, the 6' carbon of a morpholino moiety).

[0130] In an embodiment, an L 3 Attached to the 2' carbon of a single-stranded oligonucleotide. In an embodiment, one L 3 Attached to the 2' carbon of a single stranded oligonucleotide at the 5' end. 3 Attached to the 2' carbon of a single-stranded oligonucleotide at the 3' end.

[0131] In an embodiment, an L 3 Attached to the nucleobase of the single-stranded oligonucleotide. In an embodiment, an L 3 Attached to the nucleobase of the single-stranded oligonucleotide at the 3' end. In an embodiment, one L 3 Nucleobase attached to a single-stranded oligonucleotide at the 5' end.

[0132] In an embodiment, L 3 is a bond, -N(R 23 )-, -O-, -S-, -C(O)-, -N(R 23 )C(O)-、-C(O)N(R 24 )-、-N(R 23 )C(O)N(R 24 )-、-C(O)O-、-OC(O)-、-N(R 23 )C(O)O-、-OC(O)N(R 24)-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-、-OP(S)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N-、-OP(S)(NR 23 R 24 )-N-、-OP(O)(NR 23 R 24 )-O-、-OP(S)(NR 23 R 24 )-O-、-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R 24 )-O-、-P(S)(NR 23 R 24 )-O-, -SS-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0133] In an embodiment, L 3 is a bond. In an embodiment, L 3 Yes-N(R 23 )-. In the embodiment, L 3 Is -O- or -S-. In an embodiment, L 3 is -C(O)-. In an embodiment, L 3 Yes-N(R 23 )C(O)-or-C(O)N(R 24 )-. In the embodiment, L 3 Yes-N(R 23 )C(O)N(R 24 )-. In the embodiment, L 3 Is -C(O)O- or -OC(O)-. In the embodiment, L 3 Yes-N(R 23 )C(O)O-or-OC(O)N(R 24 )-. In the embodiment, L 3 Yes -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N- or OP(O)(NR23 R 24 )-O-. In the embodiment, L 3 Yes-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R 24 )-O-or-P(S)(NR 23 R 24 )-O-. In the embodiment, L 3 It's -SS-.

[0134] In an embodiment, L 3 are independently substituted or unsubstituted alkylene (e.g., C1-C 23 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 3 are independently substituted alkylene (e.g., C1-C 23 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 3 are independently unsubstituted alkylene (e.g., C1-C 23 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 3 are independently substituted or unsubstituted C1-C 23 In the embodiment, L 3 are independently substituted C1-C 23 In the embodiment, L 3 are independently unsubstituted C1-C 23 In the embodiment, L 3 are independently substituted or unsubstituted C1-C 12 In the embodiment, L 3 are independently substituted C1-C 12 In the embodiment, L 3 are independently unsubstituted C1-C 12 In the embodiment, L 3 are independently substituted or unsubstituted C1-C8 alkylene. 3 is independently substituted C1-C8 alkylene. 3 is independently unsubstituted C1-C8 alkylene. 3are independently substituted or unsubstituted C1-C6 alkylene. 3 is independently substituted C1-C6 alkylene. 3 is independently unsubstituted C1-C6 alkylene. 3 are independently substituted or unsubstituted C1-C4 alkylene. 3 is independently substituted C1-C4 alkylene. 3 is independently unsubstituted C1-C4 alkylene. 3 L is independently substituted or unsubstituted ethylene. 3 is independently substituted ethylene. 3 L is independently unsubstituted ethylene. 3 L is independently substituted or unsubstituted methylene. 3 is independently substituted methylene. 3 is independently unsubstituted methylene.

[0135] In an embodiment, L 3 is independently substituted or unsubstituted heteroalkylene (e.g., 2 to 23 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members, or 4 to 5 members). 3 is independently substituted heteroalkylene (e.g., 2 to 23 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members, or 4 to 5 members). 3 is independently unsubstituted heteroalkylene (e.g., 2 to 23 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members, or 4 to 5 members). 3 is independently a substituted or unsubstituted 2 to 23 membered heteroalkylene. 3 is independently substituted 2 to 23 membered heteroalkylene. 3 is independently an unsubstituted 2 to 23 membered heteroalkylene group. 3 is independently a substituted or unsubstituted 2 to 8 membered heteroalkylene. 3 is independently substituted 2 to 8 membered heteroalkylene. 3 is independently an unsubstituted 2 to 8 membered heteroalkylene. 3 is independently a substituted or unsubstituted 2 to 6 membered heteroalkylene. 3 is independently substituted 2 to 6 membered heteroalkylene. 3 is independently an unsubstituted 2 to 6 membered heteroalkylene.3 L is independently substituted or unsubstituted 4 to 6 membered heteroalkylene. 3 is independently substituted 4 to 6 membered heteroalkylene. 3 is independently an unsubstituted 4 to 6 membered heteroalkylene. 3 L is independently substituted or unsubstituted 2 to 3 membered heteroalkylene. 3 is independently substituted 2 to 3 membered heteroalkylene. 3 L is independently unsubstituted 2 to 3 membered heteroalkylene. 3 is independently substituted or unsubstituted 4 to 5 membered heteroalkylene. 3 is independently substituted 4 to 5 membered heteroalkylene. 3 and independently unsubstituted 4- to 5-membered heteroalkylene.

[0136] In an embodiment, L 4 is a bond, -N(R 23 )-, -O-, -S-, -C(O)-, -N(R 23 )C(O)-、-C(O)N(R 24 )-、-N(R 23 )C(O)N(R 24 )-、-C(O)O-、-OC(O)-、-N(R 23 )C(O)O-、-OC(O)N(R 24 )-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-、-OP(S)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N-、-OP(S)(NR 23 R 24 )-N-、-OP(O)(NR 23 R 24 )-O-、-OP(S)(NR 23 R 24 )-O-、-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R 24 )-O-、-P(S)(NR 23 R 24)-O-, -SS-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0137] In an embodiment, L 4 is a bond. In an embodiment, L 4 Yes-N(R 23 )-. In the embodiment, L 4 Is -O- or -S-. In an embodiment, L 4 is -C(O)-. In an embodiment, L 4 Yes-N(R 23 )C(O)-or-C(O)N(R 24 )-. In the embodiment, L 4 Yes-N(R 23 )C(O)N(R 24 )-. In the embodiment, L 4 Is -C(O)O- or -OC(O)-. In the embodiment, L 4 Yes-N(R 23 )C(O)O-or-OC(O)N(R 24 )-. In the embodiment, L 4 Yes -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N- or OP(O)(NR 23 R 24 )-O-. In the embodiment, L 4 Yes-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R 24 )-O-or-P(S)(NR 23 R 24 )-O-. In the embodiment, L 4 It's -SS-.

[0138] In an embodiment, L 4 are independently substituted or unsubstituted alkylene (e.g., C1-C 23 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 4 are independently substituted alkylene (e.g., C1-C23 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 4 are independently unsubstituted alkylene (e.g., C1-C 23 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 4 are independently substituted or unsubstituted C1-C 23 In the embodiment, L 4 are independently substituted C1-C 23 In the embodiment, L 4 are independently unsubstituted C1-C 23 In the embodiment, L 4 are independently substituted or unsubstituted C1-C 12 In the embodiment, L 4 are independently substituted C1-C 12 In the embodiment, L 4 are independently unsubstituted C1-C 12 In the embodiment, L 4 are independently substituted or unsubstituted C1-C8 alkylene. 4 is independently substituted C1-C8 alkylene. 4 is independently unsubstituted C1-C8 alkylene. 4 are independently substituted or unsubstituted C1-C6 alkylene. 4 is independently substituted C1-C6 alkylene. 4 is independently unsubstituted C1-C6 alkylene. 4 are independently substituted or unsubstituted C1-C4 alkylene. 4 is independently substituted C1-C4 alkylene. 4 is independently unsubstituted C1-C4 alkylene. 4 L is independently substituted or unsubstituted ethylene. 4 is independently substituted ethylene. 4 L is independently unsubstituted ethylene. 4 L is independently substituted or unsubstituted methylene. 4 is independently substituted methylene. 4 is independently unsubstituted methylene.

[0139] In an embodiment, L 4 is independently substituted or unsubstituted heteroalkylene (e.g., 2 to 23 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members, or 4 to 5 members). 4 is independently substituted heteroalkylene (e.g., 2 to 23 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members, or 4 to 5 members). 4 is independently unsubstituted heteroalkylene (e.g., 2 to 23 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members, or 4 to 5 members). 4 is independently a substituted or unsubstituted 2 to 23 membered heteroalkylene. 4 is independently substituted 2 to 23 membered heteroalkylene. 4 is independently an unsubstituted 2 to 23 membered heteroalkylene group. 4 is independently a substituted or unsubstituted 2 to 8 membered heteroalkylene. 4 is independently substituted 2 to 8 membered heteroalkylene. 4 is independently an unsubstituted 2 to 8 membered heteroalkylene. 4 is independently a substituted or unsubstituted 2 to 6 membered heteroalkylene. 4 is independently substituted 2 to 6 membered heteroalkylene. 4 is independently an unsubstituted 2 to 6 membered heteroalkylene. 4 L is independently substituted or unsubstituted 4 to 6 membered heteroalkylene. 4 is independently substituted 4 to 6 membered heteroalkylene. 4 is independently an unsubstituted 4 to 6 membered heteroalkylene. 4 L is independently substituted or unsubstituted 2 to 3 membered heteroalkylene. 4 is independently substituted 2 to 3 membered heteroalkylene. 4 L is independently unsubstituted 2 to 3 membered heteroalkylene. 4 is independently substituted or unsubstituted 4 to 5 membered heteroalkylene. 4 is independently substituted 4 to 5 membered heteroalkylene. 4 and independently unsubstituted 4- to 5-membered heteroalkylene.

[0140] R 23 are independently hydrogen or unsubstituted alkyl (e.g., C1-C 23 、C1-C12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 23 are independently hydrogen. In an embodiment, R 23 are independently unsubstituted C1-C 23 In an embodiment, R 23 are independently hydrogen or unsubstituted C1-C 12 In an embodiment, R 23 are independently hydrogen or unsubstituted C1-C 10 In an embodiment, R 23 is independently hydrogen or unsubstituted C1-C8 alkyl. 23 are independently hydrogen or unsubstituted C1-C6 alkyl. 23 are independently hydrogen or unsubstituted C1-C4 alkyl. 23 are independently hydrogen or unsubstituted C1-C2 alkyl.

[0141] R 24 are independently hydrogen or unsubstituted alkyl (e.g., C1-C 24 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 24 are independently hydrogen. In an embodiment, R 24 are independently unsubstituted C1-C 24 In an embodiment, R 24 are independently hydrogen or unsubstituted C1-C 12 In an embodiment, R 24 are independently hydrogen or unsubstituted C1-C 10 In an embodiment, R 24 is independently hydrogen or unsubstituted C1-C8 alkyl. 24 are independently hydrogen or unsubstituted C1-C6 alkyl. 24 are independently hydrogen or unsubstituted C1-C4 alkyl. 24 are independently hydrogen or unsubstituted C1-C2 alkyl.

[0142] R 25 are independently hydrogen or unsubstituted alkyl (e.g., C1-C 25 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 25 are independently hydrogen. In an embodiment, R 25 are independently unsubstituted C1-C 25In an embodiment, R 25 are independently hydrogen or unsubstituted C1-C 12 In an embodiment, R 25 are independently hydrogen or unsubstituted C1-C 10 In an embodiment, R 25 is independently hydrogen or unsubstituted C1-C8 alkyl. 25 are independently hydrogen or unsubstituted C1-C6 alkyl. 25 are independently hydrogen or unsubstituted C1-C4 alkyl. 25 are independently hydrogen or unsubstituted C1-C2 alkyl.

[0143] In an embodiment, L 3 and L 4 and L is independently a bond, -NH-, -O-, -C(O)-, -C(O)O-, -OC(O)-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(CH3)-O-, -OP(S)(CH3)-O-, -OP(O)(N(CH3)2)-N-, -OP(O)(N(CH3)2)-O-, -OP(S)(N(CH3)2)-N-, -OP(S)(N(CH3)2)-O-, -P(O)(N(CH3)2)-N-, -P(O)(N(CH3)2)-O-, -P(S)(N(CH3)2)-O-, -P(S)(N(CH3)2)-N-, -P(S)(N(CH3)2)-O-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene. In embodiments, L 3 and L is independently a bond, -NH-, -O-, -C(O)-, -C(O)O-, -OC(O)-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(CH3)-O-, -OP(S)(CH3)-O-, -OP(O)(N(CH3)2)-N-, -OP(O)(N(CH3)2)-O-, -OP(S)(N(CH3)2)-N-, -OP(S)(N(CH3)2)-O-, -P(O)(N(CH3)2)-N-, -P(O)(N(CH3)2)-O-, -P(S)(N(CH3)2)-O-, -P(S)(N(CH3)2)-N-, -P(S)(N(CH3)2)-O-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene. In embodiments, L 4are independently a bond, -NH-, -O-, -C(O)-, -C(O)O-, -OC(O)-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(CH3)-O-, -OP(S)(CH3)-O-, -OP(O)(N(CH3)2)-N-, -OP(O)(N(CH3)2)-O-, -OP(S)(N(CH3)2)-N-, -OP(S)(N(CH3)2)-O-, -P(O)(N(CH3)2)-N-, -P(O)(N(CH3)2)-O-, -P(S)(N(CH3)2)-N-, -P(S)(N(CH3)2)-O-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.

[0144] In an embodiment, L 3 Independently In an embodiment, L 3 are independently -OPO2-O-. In an embodiment, L 3 are independently -OP(O)(S)-O-. In an embodiment, L 3 is independently -O-. In an embodiment, L 3 Independently it is –S-.

[0145] In an embodiment, L 3 Attached to the 3' nitrogen of the morpholino moiety. In an embodiment, L 3 is independently -C(O)-. In an embodiment, L 3 Attached to the 6' carbon of the morpholino moiety. In an embodiment, L 3 are independently -OP(O)(N(CH3)2)-N-. In embodiments, L 3 are independently -OP(O)(N(CH3)2)-O-. In embodiments, L 3 is independently -P(O)(N(CH3)2)-N-. In an embodiment, L 3 are independently -P(O)(N(CH3)2)-O-.

[0146] In an embodiment, L 4 L is independently substituted or unsubstituted alkylene or substituted or unsubstituted heteroalkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-. In the embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently substituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0147] In an embodiment, L 4 is independently substituted or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 4 is independently substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 4 is independently oxo-substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 4 and alkylene groups are independently unsubstituted heteroalkylene groups (eg, 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered).

[0148] In an embodiment, L 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 4 Independently is –L 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 4 Independently is –L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2).

[0149] In an embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently substituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently substituted or unsubstituted C1-C 20 In the embodiment, L 7 are independently substituted C1-C 20 In the embodiment, L 7 are independently hydroxyl (OH)-substituted C1-C 20 In the embodiment, L 7 are independently hydroxymethyl-substituted C1-C 20 In the embodiment, L 7 are independently unsubstituted C1-C 20 In the embodiment, L 7 are independently substituted or unsubstituted C1-C 12 In the embodiment, L 7 are independently substituted C1-C 12 In the embodiment, L 7 are independently hydroxyl (OH)-substituted C1-C 12 In the embodiment, L 7 are independently hydroxymethyl-substituted C1-C 12 In the embodiment, L 7 are independently unsubstituted C1-C 12 In the embodiment, L 7 are independently substituted or unsubstituted C1-C8 alkylene. 7 is independently substituted C1-C8 alkylene. 7 is independently a hydroxy (OH)-substituted C1-C8 alkylene. 7is independently a hydroxymethyl-substituted C1-C8 alkylene. 7 is independently unsubstituted C1-C8 alkylene. 7 are independently substituted or unsubstituted C1-C6 alkylene. 7 is independently substituted C1-C6 alkylene. 7 is independently a hydroxy (OH)-substituted C1-C6 alkylene. 7 is independently a hydroxymethyl-substituted C1-C6 alkylene. 7 is independently unsubstituted C1-C6 alkylene. 7 are independently substituted or unsubstituted C1-C4 alkylene. 7 is independently substituted C1-C4 alkylene. 7 is independently a hydroxy (OH)-substituted C1-C4 alkylene. 7 is independently a hydroxymethyl-substituted C1-C4 alkylene. 7 is independently unsubstituted C1-C4 alkylene. 7 are independently substituted or unsubstituted C1-C2 alkylene. 7 is independently substituted C1-C2 alkylene. 7 is independently a hydroxy (OH)-substituted C1-C2 alkylene. 7 is independently a hydroxymethyl-substituted C1-C2 alkylene. 7 and independently unsubstituted C1-C2 alkylene.

[0150] In an embodiment, L 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C1-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L7 -C(O)-NH-; and L 7 is independently substituted C1-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted C1-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently a hydroxymethyl-substituted C1-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0151] In an embodiment, L 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C3-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently substituted C3-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently a hydroxyl (OH)-substituted C3-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently a hydroxymethyl-substituted C3-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0152] In an embodiment, L 4Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C5-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently substituted C5-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted C5-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently a hydroxymethyl-substituted C5-C8 alkylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0153] In an embodiment, L 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted octylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently substituted octylene. In an embodiment, L 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently a hydroxyl (OH)-substituted octylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently unsubstituted octylene. 4 Independently is –L7 -NH-C(O)- and L 7 is independently a hydroxyl (OH)-substituted octylene. 4 Independently is –L 7 -NH-C(O)- and L 7 is independently a hydroxymethyl-substituted octylene. 4 Independently is –L 7 -NH-C(O)- and L 7 and independently unsubstituted octanylene.

[0154] In an embodiment, L 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 L is independently substituted or unsubstituted heptylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently substituted heptylene. In an embodiment, L 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted heptylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 L is independently unsubstituted heptylene. 4 Independently is –L 7 -NH-C(O)- and L 7 is independently a hydroxy (OH)-substituted heptylene. 4 Independently is –L 7 -NH-C(O)- and L 7 is independently a hydroxymethyl-substituted heptylene. 4 Independently is –L 7 -NH-C(O)- and L 7 and is independently unsubstituted heptylene.

[0155] In an embodiment, L 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L7 L is independently substituted or unsubstituted hexamethylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 L is independently substituted hexamethylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently a hydroxyl (OH)-substituted hexamethylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 L is independently unsubstituted hexamethylene. 4 Independently is –L 7 -NH-C(O)- and L 7 is independently a hydroxyl (OH)-substituted hexamethylene. 4 Independently is –L 7 -NH-C(O)- and L 7 is independently a hydroxymethyl-substituted hexamethylene. 4 Independently is –L 7 -NH-C(O)- and L 7 and is independently unsubstituted hexamethylene.

[0156] In an embodiment, L 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 L is independently substituted or unsubstituted pentylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently substituted pentylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted pentylene. 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-; and L7 L is independently unsubstituted pentylene. 4 Independently is –L 7 -NH-C(O)- and L 7 is independently a hydroxy (OH)-substituted pentylene. 4 Independently is –L 7 -NH-C(O)- and L 7 is independently hydroxymethyl-substituted pentylene. In an embodiment, L 4 Independently is –L 7 -NH-C(O)- and L 7 is independently unsubstituted pentylene.

[0157] In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently

[0158] In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently

[0159] In the embodiment, –L 3 -L 4 -Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-. In the embodiment, L 7 is independently substituted or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7is independently substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently oxo-substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently substituted or unsubstituted heteroalkenylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently substituted heteroalkenylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently oxo-substituted heteroalkenylene (e.g., 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 members). 7 is independently unsubstituted heteroalkenylene (eg, 2-20 membered, 2-12 membered, 2-10 membered, 2-8 membered, 2-6 membered, or 2-4 membered).

[0160] In an embodiment, L 7 is independently a substituted or unsubstituted 2 to 20 membered heteroalkylene group. 7 is independently substituted 2 to 20 membered heteroalkylene. 7 is independently oxo-substituted 2 to 20 membered heteroalkylene. 7 L is independently unsubstituted 2 to 20 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2 to 12 membered heteroalkylene. 7 is independently substituted 2 to 12 membered heteroalkylene. 7 is independently oxo-substituted 2 to 12 membered heteroalkylene. 7 is independently an unsubstituted 2 to 12 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2 to 10 membered heteroalkylene. 7 is independently substituted 2 to 10 membered heteroalkylene. 7 is independently oxo-substituted 2 to 10 membered heteroalkylene. 7 is independently an unsubstituted 2 to 10 membered heteroalkylene. 7is independently a substituted or unsubstituted 2 to 8 membered heteroalkylene. 7 is independently substituted 2 to 8 membered heteroalkylene. 7 is independently oxo-substituted 2 to 8 membered heteroalkylene. 7 is independently an unsubstituted 2 to 8 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2 to 6 membered heteroalkylene. 7 is independently substituted 2 to 6 membered heteroalkylene. 7 is independently oxo-substituted 2 to 6 membered heteroalkylene. 7 is independently an unsubstituted 2 to 6 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2 to 4 membered heteroalkylene. 7 is independently substituted 2 to 4 membered heteroalkylene. 7 is independently oxo-substituted 2 to 4 membered heteroalkylene. 7 and independently unsubstituted 2- to 4-membered heteroalkylene.

[0161] In an embodiment, L 7 L is independently substituted or unsubstituted 2 to 20 membered heteroalkenylene. 7 L is independently substituted 2 to 20 membered heteroalkenylene. 7 is independently oxo-substituted 2 to 20 membered heteroalkenylene. 7 L is independently unsubstituted 2 to 20 membered heteroalkenylene. 7 L is independently substituted or unsubstituted 2 to 12 membered heteroalkenylene. 7 is independently substituted 2 to 12 membered heteroalkenylene. 7 is independently oxo-substituted 2 to 12 membered heteroalkenylene. 7 L is independently unsubstituted 2 to 12 membered heteroalkenylene. 7 L is independently substituted or unsubstituted 2 to 10 membered heteroalkenylene. 7 is independently substituted 2 to 10 membered heteroalkenylene. 7 is independently oxo-substituted 2 to 10 membered heteroalkenylene. 7 L is independently unsubstituted 2 to 10 membered heteroalkenylene. 7 L is independently substituted or unsubstituted 2 to 8 membered heteroalkenylene. 7L is independently substituted 2 to 8 membered heteroalkenylene. 7 is independently oxo-substituted 2 to 8 membered heteroalkenylene. 7 L is independently unsubstituted 2 to 8 membered heteroalkenylene. 7 L is independently substituted or unsubstituted 2 to 6 membered heteroalkenylene. 7 L is independently substituted 2 to 6 membered heteroalkenylene. 7 is independently oxo-substituted 2 to 6 membered heteroalkenylene. 7 L is independently unsubstituted 2 to 6 membered heteroalkenylene. 7 L is independently substituted or unsubstituted 2 to 4 membered heteroalkenylene. 7 L is independently substituted 2 to 4 membered heteroalkenylene. 7 is independently oxo-substituted 2 to 4 membered heteroalkenylene. 7 and independently unsubstituted 2- to 4-membered heteroalkenylene.

[0162] In the embodiment, –L 3 -L 4 -Independently is –OL 7 -NH-C(O)- or -OL 7 -C(O)-NH-. In the embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, –L 3 -L 4 -Independently is –OL 7 -NH-C(O)- or -OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, –L 3 -L 4 -Independently is –OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, –L 3 -L 4-Independently is –OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0163] In the embodiment, –L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C1-C8 alkylene. In the embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7 is independently substituted C1-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH- and L 7 is independently a hydroxymethyl-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0164] In the embodiment, –L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7 is independently substituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7is independently a hydroxy (OH)-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH- and L 7 is independently a hydroxymethyl-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0165] In the embodiment, –L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7 is independently substituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted C5-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH- and L 7 is independently a hydroxymethyl-substituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is –OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0166] In the embodiment, –L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted C1-C8 alkylene. In the embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7is independently substituted C1-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 is independently a hydroxy (OH)-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 is independently a hydroxymethyl-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0167] In the embodiment, –L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 is independently substituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 is independently a hydroxy (OH)-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 is independently a hydroxymethyl-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0168] In the embodiment, –L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7are independently substituted or unsubstituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 is independently substituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 is independently a hydroxy (OH)-substituted C5-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 is independently a hydroxymethyl-substituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently is-OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0169] In the embodiment, –L 3 -L 4 - Independently In the embodiment, –L 3 -L 4 - Independently In the embodiment, –L 3 -L 4 - Independently In the embodiment, –L 3 -L 4 - Independently

[0170] In the embodiment, –L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-、-OP(O)(S)-OL 7 -NH-C(O)-、-OPO2-OL 7 -C(O)-NH- or –OP(O)(S)-OL 7 -C(O)-NH-. In the embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, –L3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)- or -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted alkylene. In an embodiment, -L 3 -L 4 - independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-or–OP(O)(S)-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene. In an embodiment, -L 3 -L 4 - independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 and are independently substituted or unsubstituted alkylene.

[0171] In the embodiment, –L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)- or -OPO2-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, –L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, –L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0172] In the embodiment, –L 3 -L 4 - independently -OP(O)(S)-OL 7 -NH-C(O)- or -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, –L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, –L 3 -L 4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0173] In the embodiment, –L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C1-C8 alkylene. In the embodiment, -L 3 -L4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently substituted C1-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a hydroxymethyl-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0174] In the embodiment, –L 3 -L 4 - independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C1-C8 alkylene. In the embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 is independently substituted C1-C8 alkylene. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 is independently a hydroxymethyl-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0175] In the embodiment, –L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently substituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a hydroxymethyl-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0176] In the embodiment, –L 3 -L 4 - independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 is independently substituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7-C(O)-NH-; and L 7 is independently a hydroxymethyl-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0177] In the embodiment, –L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently substituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted C5-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a hydroxymethyl-substituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0178] In the embodiment, –L 3 -L 4 - independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 is independently substituted C5-C8 alkylene. In an embodiment, -L 3 -L4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH)-substituted C5-C8 alkylene group. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 is independently a hydroxymethyl-substituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0179] In the embodiment, –L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted C1-C8 alkylene. In the embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently substituted C1-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a hydroxy (OH)-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a hydroxymethyl-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0180] In the embodiment, –L 3 -L 4 - independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7are independently substituted or unsubstituted C1-C8 alkylene. In the embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 is independently substituted C1-C8 alkylene. In an embodiment, -L 3 -L 4 independently -OP(O)(S)2-OL 7 -NH-C(O)-; and L 7 is independently a hydroxy (OH)-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 is independently a hydroxymethyl-substituted C1-C8 alkylene group. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0181] In the embodiment, –L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently substituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a hydroxy (OH)-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a hydroxymethyl-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7-NH-C(O)-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0182] In the embodiment, –L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 is independently substituted C3-C8 alkylene. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 is independently a hydroxy (OH)-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 is independently a hydroxymethyl-substituted C3-C8 alkylene group. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0183] In the embodiment, –L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently substituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a hydroxy (OH)-substituted C5-C8 alkylene group. In an embodiment, -L 3-L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a hydroxymethyl-substituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0184] In the embodiment, –L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 is independently substituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 is independently a hydroxy (OH)-substituted C5-C8 alkylene group. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 is independently a hydroxymethyl-substituted C5-C8 alkylene. In an embodiment, -L 3 -L 4 - is independently -OP(O)(S)-OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0185] In the embodiment, –L 3 -L 4 - Independently

[0186]

[0187] In the embodiment, –L 3 -L 4 - Independently In the embodiment, –L 3 -L 4 - Independently In the embodiment, –L 3 -L 4 - Independently

[0188] In the embodiment, –L 3 -L 4 - Independently In the embodiment, –L 3 -L 4 - Independently

[0189] In the embodiment, –L 3 -L 4 - Independently and attached to the 3' carbon of the oligonucleotide.

[0190] In the embodiment, –L 3 -L 4 - is independently attached to the 3' carbon of the oligonucleotide In the embodiment, –L 3 -L 4 - is independently attached to the 3' carbon of the oligonucleotide

[0191]

[0192]

[0193] In the embodiment, –L 3 -L 4 - Independently and is attached to the 3' nitrogen of the oligonucleotide (eg, the 3' nitrogen of the morpholino moiety).

[0194] In the embodiment, –L 3 -L 4 - is independently attached to the 3' nitrogen of the oligonucleotide (eg, the 3' nitrogen of the morpholino moiety) In the embodiment, –L 3 -L 4 - is independently attached to the 3' nitrogen of the oligonucleotide (eg, the 3' nitrogen of the morpholino moiety)

[0195] In the embodiment, –L 3 -L 4 - Independently and attached to the 5' carbon of the oligonucleotide. In an embodiment, -L 3 -L 4 - is independently attached to the 5' carbon of the oligonucleotide In the embodiment, –L 3 -L 4 - is independently attached to the 5' carbon of the oligonucleotide

[0196] In the embodiment, –L 3 -L 4 - is independently attached to the 6' carbon of the oligonucleotide (e.g., the 6' carbon of the morpholino moiety) In the embodiment, –L 3 -L 4 - is independently attached to the 6' carbon of the oligonucleotide (e.g., the 6' carbon of the morpholino moiety) In the embodiment, –L 3 -L 4 - is independently attached to the 6' carbon of the oligonucleotide (e.g., the 6' carbon of the morpholino moiety)

[0197] In the embodiment, –L 3 -L 4 - independently attached to the nucleobase of the oligonucleotide. In an embodiment, -L 3 -L 4 - Independently and attached to the nucleobases of the oligonucleotide.

[0198] In an embodiment, -L 3 -L 4 - Attached at the 3' end to the 3' carbon of a single-stranded oligonucleotide.

[0199] In an embodiment, -L 3 -L 4 - Attached at the 3' end to the 3' nitrogen of a single-stranded oligonucleotide (eg, the 3' nitrogen of a morpholino moiety).

[0200] In an embodiment, -L 3 -L 4 - Attached to the 5' carbon of a single stranded oligonucleotide at its 5' end.

[0201] In an embodiment, -L 3 -L 4 - is attached to the 6' carbon of a single-stranded oligonucleotide at its 5' end (eg, the 6' carbon of a morpholino moiety). In an embodiment, -L 3 -L4 - Independently

[0202] In an embodiment, -L 3 -L 4 - is attached to the 2' carbon of a single-stranded oligonucleotide. In an embodiment, -L 3 -L 4 - is attached to the 2' carbon of a single stranded oligonucleotide at the 3' end. In an embodiment, -L 3 -L 4 - Attached to the 2' carbon of a single-stranded oligonucleotide at the 5' end.

[0203] In an embodiment, -L 3 -L 4 - attached to a nucleobase of a single-stranded oligonucleotide. In an embodiment, -L 3 -L 4 - a nucleobase attached to a single-stranded oligonucleotide at its 3' end. In an embodiment, -L 3 -L 4 - a nucleobase attached at its 5' end to a single-stranded oligonucleotide.

[0204] In the embodiment, –L 3 -L 4 - Independently

[0205]

[0206] In the embodiment, –L 3 -L 4 - is independently attached to the 3' carbon of the oligonucleotide

[0207] In the embodiment, –L 3 -L 4 - is independently attached to the 5' carbon of the oligonucleotide

[0208] In the embodiment, –L 3 -L 4 - is independently attached to the 3' carbon of the oligonucleotide In the embodiment, –L 3 -L 4 - is independently attached to the 5' carbon of the oligonucleotide

[0209] In the embodiment, –L 3 -L 4 - is independently attached to the 3' carbon of the oligonucleotide In the embodiment, –L 3 -L 4- Independently and attached to the 5' carbon of the oligonucleotide. In an embodiment, -L 3 -L 4 - is independently attached to the 6' carbon of the oligonucleotide (e.g., the 6' carbon of the morpholino moiety) In the embodiment, –L 3 -L 4 - Independently and attached to the 2' carbon of the oligonucleotide.

[0210] In the embodiment, –L 3 -L 4 - is independently attached to the 2' carbon of the oligonucleotide In the embodiment, –L 3 -L 4 - Independently and attached to the nucleobases of the oligonucleotide.

[0211] In an embodiment, R 3 and -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, R 3 are independently hydrogen. In an embodiment, R 3 is independently -NH2. In an embodiment, R 3 is independently -OH. In an embodiment, R 3 is independently -SH. In an embodiment, R 3 is independently -C(O)H. In an embodiment, R 3 is independently -C(O)NH2. In an embodiment, R 3 is independently -NHC(O)H. In an embodiment, R 3 is independently -NHC(O)OH. In an embodiment, R 3 is independently -NHC(O)NH2. In an embodiment, R 3 is independently -C(O)OH. In an embodiment, R 3 is independently -OC(O)H. In an embodiment, R 3 Independently -N3.

[0212] In an embodiment, R 3 are independently substituted or unsubstituted alkyl (e.g., C1-C 20 、C1-C12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 3 are independently substituted or unsubstituted C1-C 20 In an embodiment, R 3 are independently substituted C1-C 20 In an embodiment, R 3 are independently unsubstituted C1-C 20 In an embodiment, R 3 are independently substituted or unsubstituted C1-C 12 In an embodiment, R 3 are independently substituted C1-C 12 In an embodiment, R 3 are independently unsubstituted C1-C 12 In an embodiment, R 3 are independently substituted or unsubstituted C1-C8 alkyl. 3 is independently substituted C1-C8 alkyl. 3 is independently unsubstituted C1-C8 alkyl. 3 are independently substituted or unsubstituted C1-C6 alkyl. 3 is independently substituted C1-C6 alkyl. 3 is independently unsubstituted C1-C6 alkyl. 3 are independently substituted or unsubstituted C1-C4 alkyl. 3 is independently substituted C1-C4 alkyl. 3 is independently unsubstituted C1-C4 alkyl. 3 is independently substituted or unsubstituted ethyl. 3 is independently substituted ethyl. In an embodiment, R 3 is independently unsubstituted ethyl. 3 is independently substituted or unsubstituted methyl. 3 is independently substituted methyl. In an embodiment, R 3 is independently unsubstituted methyl.

[0213] In an embodiment, L 6 is independently -NHC(O)-. In an embodiment, L 6 are independently -C(O)NH-. In an embodiment, L 6 are independently substituted or unsubstituted alkylene. 6and are independently substituted or unsubstituted heteroalkylene.

[0214] In an embodiment, L 6 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 6 are independently substituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4, or C1-C2). In an embodiment, L 6 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4, or C1-C2). In an embodiment, L 6 are independently substituted or unsubstituted C1-C 20 In the embodiment, L 6 are independently substituted C1-C 20 In the embodiment, L 6 are independently unsubstituted C1-C 20 In the embodiment, L 6 are independently substituted or unsubstituted C1-C 12 In the embodiment, L 6 are independently substituted C1-C 12 In the embodiment, L 6 are independently unsubstituted C1-C 12 In the embodiment, L 6 are independently substituted or unsubstituted C1-C8 alkylene. 6 is independently substituted C1-C8 alkylene. 6 is independently unsubstituted C1-C8 alkylene. 6 are independently substituted or unsubstituted C1-C6 alkylene. 6 is independently substituted C1-C6 alkylene. 6 is independently unsubstituted C1-C6 alkylene. 6 are independently substituted or unsubstituted C1-C4 alkylene. 6 is independently substituted C1-C4 alkylene. 6 is independently unsubstituted C1-C4 alkylene. 6L is independently substituted or unsubstituted ethylene. 6 is independently substituted ethylene. 6 L is independently unsubstituted ethylene. 6 L is independently substituted or unsubstituted methylene. 6 is independently substituted methylene. 6 is independently unsubstituted methylene.

[0215] In an embodiment, L 6 is independently substituted or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered, or 4 to 5-membered). 6 is independently substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered, or 4 to 5-membered). 6 is independently unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered, or 4 to 5-membered). 6 is independently a substituted or unsubstituted 2 to 20 membered heteroalkylene group. 6 is independently substituted 2 to 20 membered heteroalkylene. 6 L is independently unsubstituted 2 to 20 membered heteroalkylene. 6 is independently a substituted or unsubstituted 2 to 8 membered heteroalkylene. 6 is independently substituted 2 to 8 membered heteroalkylene. 6 is independently an unsubstituted 2 to 8 membered heteroalkylene. 6 is independently a substituted or unsubstituted 2 to 6 membered heteroalkylene. 6 is independently substituted 2 to 6 membered heteroalkylene. 6 is independently an unsubstituted 2 to 6 membered heteroalkylene. 6 L is independently substituted or unsubstituted 4 to 6 membered heteroalkylene. 6 is independently substituted 4 to 6 membered heteroalkylene. 6 is independently an unsubstituted 4 to 6 membered heteroalkylene. 6 L is independently substituted or unsubstituted 2 to 3 membered heteroalkylene. 6 is independently substituted 2 to 3 membered heteroalkylene. 6 L is independently unsubstituted 2 to 3 membered heteroalkylene.6 is independently substituted or unsubstituted 4 to 5 membered heteroalkylene. 6 is independently substituted 4 to 5 membered heteroalkylene. 6 and independently unsubstituted 4- to 5-membered heteroalkylene.

[0216] In an embodiment, L 6A L is independently a bond or unsubstituted alkylene; 6B are independently a bond, -NHC(O)- or unsubstituted arylene; L 6C L is independently a bond, unsubstituted alkylene, or unsubstituted arylene; 6D are independently a bond or unsubstituted alkylene; and L 6E is independently a bond or -NHC(O)-. In an embodiment, L 6A is independently a bond or an unsubstituted alkylene. 6B is independently a bond, -NHC(O)- or unsubstituted arylene. 6C L is independently a bond, an unsubstituted alkylene group, or an unsubstituted arylene group. 6D is independently a bond or an unsubstituted alkylene. 6E is independently a bond or -NHC(O)-.

[0217] In an embodiment, L 6A are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 6A are independently unsubstituted C1-C 20 In the embodiment, L 6A are independently unsubstituted C1-C 12 In the embodiment, L 6A is independently unsubstituted C1-C8 alkylene. 6A is independently unsubstituted C1-C6 alkylene. 6A is independently unsubstituted C1-C4 alkylene. 6A L is independently unsubstituted ethylene. 6A L is independently unsubstituted methylene. 6A Independently is the key.

[0218] In an embodiment, L 6B are independently a bond. In an embodiment, L 6B is independently -NHC(O)-. In an embodiment, L6B are independently unsubstituted arylene groups (e.g., C6-C 12 、C6-C 10 or phenyl). In an embodiment, L 6B are independently unsubstituted C6-C 12 In the embodiment, L 6B are independently unsubstituted C6-C 10 In the embodiment, L 6B is independently unsubstituted phenylene. 6B L is independently unsubstituted naphthylene. 6B and independently unsubstituted biphenylene.

[0219] In an embodiment, L 6C are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 6C are independently unsubstituted C1-C 20 In the embodiment, L 6C are independently unsubstituted C1-C 12 In the embodiment, L 6C are independently unsubstituted C1-C8 alkylene. 6C L is independently unsubstituted C2-C8 alkynylene. 6C is independently unsubstituted C1-C6 alkylene. 6C is independently unsubstituted C1-C4 alkylene. 6C L is independently unsubstituted ethylene. 6C L is independently unsubstituted methylene. 6C is independently a bond or an unsubstituted alkynylene (e.g., C2-C 20 、C2-C 12 , C2-C8, C2-C6, C2-C4 or C2-C2). In an embodiment, L 6C are independently unsubstituted C2-C 20 In an embodiment, L 6C are independently unsubstituted C2-C 12 In an embodiment, L 6C L is independently unsubstituted C2-C8 alkynylene. 6C is independently unsubstituted C2-C6 alkynylene. 6Cis independently unsubstituted C2-C4 alkynylene. 6C L is independently unsubstituted ethynylene. 6C are independently unsubstituted arylene groups (e.g., C6-C 12 、C6-C 10 or phenyl). In an embodiment, L 6C are independently unsubstituted C6-C 12 In the embodiment, L 6C are independently unsubstituted C6-C 10 In the embodiment, L 6C is independently unsubstituted phenylene. 6C L is independently unsubstituted naphthylene. 6C Independently is the key.

[0220] In an embodiment, L 6D are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 6D are independently unsubstituted C1-C 20 In the embodiment, L 6D are independently unsubstituted C1-C 12 In the embodiment, L 6A is independently unsubstituted C1-C8 alkylene. 6D is independently unsubstituted C1-C6 alkylene. 6D is independently unsubstituted C1-C4 alkylene. 6D L is independently unsubstituted ethylene. 6D L is independently unsubstituted methylene. 6D Independently is the key.

[0221] In an embodiment, L 6E are independently a bond. In an embodiment, L 6E is independently -NHC(O)-.

[0222] In an embodiment, L 6A is independently a bond or an unsubstituted C1-C8 alkylene. 6B is independently a bond, -NHC(O)- or unsubstituted phenylene. 6C L is independently a bond, an unsubstituted C2-C8 alkynylene, or an unsubstituted phenylene. 6Dis independently a bond or an unsubstituted C1-C8 alkylene. 6E is independently a bond or -NHC(O)-.

[0223] In an embodiment, L 6 independently are keys, In an embodiment, L 6 are independently a bond. In an embodiment, L 6 Independently In an embodiment, L 6 Independently In an embodiment, L 6 Independently In an embodiment, L 6 Independently In an embodiment, L 6 Independently

[0224] In an embodiment, L 5 is independently -NHC(O)-. In an embodiment, L 5 are independently -C(O)NH-. In an embodiment, L 5 are independently substituted or unsubstituted alkylene. 5 and are independently substituted or unsubstituted heteroalkylene.

[0225] In an embodiment, L 5 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5 are independently substituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5 are independently substituted or unsubstituted C1-C 20 In the embodiment, L 5 are independently substituted C1-C 20 In the embodiment, L 5 are independently unsubstituted C1-C 20 In the embodiment, L5 are independently substituted or unsubstituted C1-C 12 In the embodiment, L 5 are independently substituted C1-C 12 In the embodiment, L 5 are independently unsubstituted C1-C 12 In the embodiment, L 5 are independently substituted or unsubstituted C1-C8 alkylene. 5 is independently substituted C1-C8 alkylene. 5 is independently unsubstituted C1-C8 alkylene. 5 are independently substituted or unsubstituted C1-C6 alkylene. 5 is independently substituted C1-C6 alkylene. 5 is independently unsubstituted C1-C6 alkylene. 5 are independently substituted or unsubstituted C1-C4 alkylene. 5 is independently substituted C1-C4 alkylene. 5 is independently unsubstituted C1-C4 alkylene. 5 L is independently substituted or unsubstituted ethylene. 5 is independently substituted ethylene. 5 L is independently unsubstituted ethylene. 5 L is independently substituted or unsubstituted methylene. 5 is independently substituted methylene. 5 is independently unsubstituted methylene.

[0226] In an embodiment, L 5 is independently substituted or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered, or 4 to 5-membered). 5 is independently substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered, or 4 to 5-membered). 5 is independently unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered, or 4 to 5-membered). 5 is independently a substituted or unsubstituted 2 to 20 membered heteroalkylene group. 5is independently substituted 2 to 20 membered heteroalkylene. 5 L is independently unsubstituted 2 to 20 membered heteroalkylene. 5 is independently a substituted or unsubstituted 2 to 8 membered heteroalkylene. 5 is independently substituted 2 to 8 membered heteroalkylene. 5 is independently an unsubstituted 2 to 8 membered heteroalkylene. 5 is independently a substituted or unsubstituted 2 to 6 membered heteroalkylene. 5 is independently substituted 2 to 6 membered heteroalkylene. 5 is independently an unsubstituted 2 to 6 membered heteroalkylene. 5 L is independently substituted or unsubstituted 4 to 6 membered heteroalkylene. 5 is independently substituted 4 to 6 membered heteroalkylene. 5 is independently an unsubstituted 4 to 6 membered heteroalkylene. 5 L is independently substituted or unsubstituted 2 to 3 membered heteroalkylene. 5 is independently substituted 2 to 3 membered heteroalkylene. 5 L is independently unsubstituted 2 to 3 membered heteroalkylene. 5 is independently substituted or unsubstituted 4 to 5 membered heteroalkylene. 5 is independently substituted 4 to 5 membered heteroalkylene. 5 and independently unsubstituted 4- to 5-membered heteroalkylene.

[0227] In an embodiment, L 5A L is independently a bond or unsubstituted alkylene; 5B are independently a bond, -NHC(O)- or unsubstituted arylene; L 5C L is independently a bond, unsubstituted alkylene, or unsubstituted arylene; 5D are independently a bond or unsubstituted alkylene; and L 5E is independently a bond or -NHC(O)-. In an embodiment, L 5A is independently a bond or an unsubstituted alkylene. 5B is independently a bond, -NHC(O)- or unsubstituted arylene. 5C L is independently a bond, an unsubstituted alkylene group, or an unsubstituted arylene group. 5D is independently a bond or an unsubstituted alkylene. 5Eis independently a bond or -NHC(O)-.

[0228] In an embodiment, L 5A are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5A are independently unsubstituted C1-C 20 In the embodiment, L 5A are independently unsubstituted C1-C 12 In the embodiment, L 5A is independently unsubstituted C1-C8 alkylene. 5A is independently unsubstituted C1-C6 alkylene. 5A is independently unsubstituted C1-C4 alkylene. 5A L is independently unsubstituted ethylene. 5A L is independently unsubstituted methylene. 5A Independently is the key.

[0229] In an embodiment, L 5B are independently a bond. In an embodiment, L 5B is independently -NHC(O)-. In an embodiment, L 5B are independently unsubstituted arylene groups (e.g., C6-C 12 、C6-C 10 or phenyl). In an embodiment, L 5B are independently unsubstituted C6-C 12 In the embodiment, L 5B are independently unsubstituted C6-C 10 In the embodiment, L 5B is independently unsubstituted phenylene. 5B is independently unsubstituted naphthylene.

[0230] In an embodiment, L 5C are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5C are independently unsubstituted C1-C 20 In the embodiment, L 5C are independently unsubstituted C1-C 12 In the embodiment, L 5Care independently unsubstituted C1-C8 alkylene. 5C L is independently unsubstituted C2-C8 alkynylene. 5C is independently unsubstituted C1-C6 alkylene. 5C is independently unsubstituted C1-C4 alkylene. 5C L is independently unsubstituted ethylene. 5C L is independently unsubstituted methylene. 5C is independently a bond or an unsubstituted alkynylene (e.g., C2-C 20 、C2-C 12 , C2-C8, C2-C6, C2-C4 or C2-C2). In an embodiment, L 5C are independently unsubstituted C2-C 20 In an embodiment, L 5C are independently unsubstituted C2-C 12 In an embodiment, L 5C L is independently unsubstituted C2-C8 alkynylene. 5C is independently unsubstituted C2-C6 alkynylene. 5C is independently unsubstituted C2-C4 alkynylene. 5C L is independently unsubstituted ethynylene. 5C are independently unsubstituted arylene groups (e.g., C6-C 12 、C6-C 10 or phenyl). In an embodiment, L 5C are independently unsubstituted C6-C 12 In the embodiment, L 5C are independently unsubstituted C6-C 10 In the embodiment, L 5C is independently unsubstituted phenylene. 5C L is independently unsubstituted naphthylene. 5C Independently is the key.

[0231] In an embodiment, L 5D are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5D are independently unsubstituted C1-C 20 In the embodiment, L 5D are independently unsubstituted C1-C12 In the embodiment, L 5A is independently unsubstituted C1-C8 alkylene. 5D is independently unsubstituted C1-C6 alkylene. 5D is independently unsubstituted C1-C4 alkylene. 5D L is independently unsubstituted ethylene. 5D L is independently unsubstituted methylene. 5D Independently is the key.

[0232] In an embodiment, L 5E are independently a bond. In an embodiment, L 5E is independently -NHC(O)-.

[0233] In an embodiment, L 5A is independently a bond or an unsubstituted C1-C8 alkylene. 5B is independently a bond, -NHC(O)- or unsubstituted phenylene. 5C L is independently a bond, an unsubstituted C2-C8 alkynylene, or an unsubstituted phenylene. 5D is independently a bond or an unsubstituted C1-C8 alkylene. 5E is independently a bond or -NHC(O)-.

[0234] In an embodiment, L 5 independently are keys, In an embodiment, L 5 are independently a bond. In an embodiment, L 5 Independently In an embodiment, L 5 Independently In an embodiment, L 5 Independently In an embodiment, L 5 Independently In an embodiment, L 5 Independently

[0235] In an embodiment, R 1 is an unsubstituted alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R1 is an unsubstituted unbranched alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 is an unsubstituted unbranched saturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 is an unsubstituted unbranched unsaturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0236] In an embodiment, R 1 is an unsubstituted C1-C 17 In an embodiment, R 1 is unsubstituted C 11 -C 17 In an embodiment, R 1 is unsubstituted C 13 -C 17 In an embodiment, R 1 is unsubstituted C 14 -C 15 In an embodiment, R 1 is unsubstituted C 15 In an embodiment, R 1 is unsubstituted C 14 alkyl.

[0237] In an embodiment, R 1 It is an unsubstituted unbranched C1-C 17 In an embodiment, R 1 is an unsubstituted unbranched C 11 -C 17 In an embodiment, R 1 is an unsubstituted unbranched C 13 -C 17 In an embodiment, R 1 is an unsubstituted unbranched C 14 -C 15 In an embodiment, R 1 is an unsubstituted unbranched C14 In an embodiment, R 1 is an unsubstituted unbranched C 15 alkyl.

[0238] In an embodiment, R 1 It is an unsubstituted unbranched saturated C1-C 17 In an embodiment, R 1 is an unsubstituted unbranched saturated C 11 -C 17 In an embodiment, R 1 is an unsubstituted unbranched saturated C 13 -C 17 In an embodiment, R 1 is an unsubstituted unbranched saturated C 14 -C 15 In an embodiment, R 1 is an unsubstituted unbranched saturated C 14 In an embodiment, R 1 is an unsubstituted unbranched saturated C 15 alkyl.

[0239] In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C1-C 17 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C 11 -C 17 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C 13 -C 17 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C 14 -C 15 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C 14 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C 15 alkyl.

[0240] In an embodiment, R 2 is an unsubstituted alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 is an unsubstituted unbranched alkyl group (e.g., C1-C 25 、C1-C 20、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 is an unsubstituted unbranched saturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0241] In an embodiment, R 2 is an unsubstituted unbranched unsaturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0242] In an embodiment, R 2 is an unsubstituted C1-C 17 In an embodiment, R 2 is unsubstituted C 11 -C 17 In an embodiment, R 2 is unsubstituted C 13 -C 17 In an embodiment, R 2 is unsubstituted C 14 -C 15 In an embodiment, R 2 is unsubstituted C 14 In an embodiment, R 2 is unsubstituted C 15 alkyl.

[0243] In an embodiment, R 2 It is an unsubstituted unbranched C1-C 17 In an embodiment, R 2 is an unsubstituted unbranched C 11 -C 17 In an embodiment, R 2 is an unsubstituted unbranched C 13 -C 17 In an embodiment, R 2 is an unsubstituted unbranched C 14 -C 15 In an embodiment, R 2 is an unsubstituted unbranched C 14 In an embodiment, R 2is an unsubstituted unbranched C 15 alkyl.

[0244] In an embodiment, R 2 It is an unsubstituted unbranched saturated C1-C 17 In an embodiment, R 2 is an unsubstituted unbranched saturated C 11 -C 17 In an embodiment, R 2 is an unsubstituted unbranched saturated C 13 -C 17 In an embodiment, R 2 is an unsubstituted unbranched saturated C 14 -C 15 In an embodiment, R 2 is an unsubstituted unbranched saturated C 14 In an embodiment, R 2 is an unsubstituted unbranched saturated C 15 alkyl.

[0245] In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C1-C 17 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 11 -C 17 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 13 -C 17 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 14 -C 15 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 14 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 15 alkyl.

[0246] In an embodiment, R 1 and R 2 At least one of them is unsubstituted C1-C 19 In an embodiment, R 1 and R 2 At least one of them is unsubstituted C9-C 19 In an embodiment, R 1 and R 2 At least one of them is unsubstituted C 11 -C 19 In an embodiment, R 1 and R2 At least one of them is unsubstituted C 13 -C 19 alkyl.

[0247] In an embodiment, R 1 is an unsubstituted C1-C 19 In an embodiment, R 1 is unsubstituted C9-C 19 In an embodiment, R 1 is unsubstituted C 11 -C 19 In an embodiment, R 1 is unsubstituted C 13 -C 19 In an embodiment, R 1 It is an unsubstituted unbranched C1-C 19 In an embodiment, R 1 It is an unsubstituted unbranched C9-C 19 In an embodiment, R 1 is an unsubstituted unbranched C 11 -C 19 In an embodiment, R 1 is an unsubstituted unbranched C 13 -C 19 In an embodiment, R 1 It is an unsubstituted unbranched saturated C1-C 19 In an embodiment, R 1 It is an unsubstituted unbranched saturated C9-C 19 In an embodiment, R 1 is an unsubstituted unbranched saturated C 11 -C 19 In an embodiment, R 1 is an unsubstituted unbranched saturated C 13 -C 19 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C1-C 19 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C9-C 19 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C 11 -C 19 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C 13 -C 19 alkyl.

[0248] In an embodiment, R 2is an unsubstituted C1-C 19 In an embodiment, R 2 is unsubstituted C9-C 19 In an embodiment, R 2 is unsubstituted C 11 -C 19 In an embodiment, R 2 is unsubstituted C 13 -C 19 In an embodiment, R 2 It is an unsubstituted unbranched C1-C 19 In an embodiment, R 2 It is an unsubstituted unbranched C9-C 19 In an embodiment, R 2 is an unsubstituted unbranched C 11 -C 19 In an embodiment, R 2 is an unsubstituted unbranched C 13 -C 19 In an embodiment, R 2 It is an unsubstituted unbranched saturated C1-C 19 In an embodiment, R 2 It is an unsubstituted unbranched saturated C9-C 19 In an embodiment, R 2 is an unsubstituted unbranched saturated C 11 -C 19 In an embodiment, R 2 is an unsubstituted unbranched saturated C 13 -C 19 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C1-C 19 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C9-C 19 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 11 -C 19 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 13 -C 19 alkyl.

[0249] L 3 are independently a bond, a bond, -N(R 23 )-, -O-, -S-, -C(O)-, -N(R 23 )C(O)-、-C(O)N(R 24 )-、-N(R 23)C(O)N(R 24 )-、-C(O)O-、-OC(O)-、-N(R 23 )C(O)O-、-OC(O)N(R 24 )-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-、-OP(S)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N-、-OP(S)(NR 23 R 24 )-N-、-OP(O)(NR 23 R 24 )-O-、-OP(S)(NR 23 R 24 )-O-、-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R 24 )-O-、-P(S)(NR 23 R 24 )-O-, -SS-, substituted (eg, substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted alkylene (eg, C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 3 are independently a bond, a bond, -N(R 23 )-, -O-, -S-, -C(O)-, -N(R 23 )C(O)-、-C(O)N(R 24 )-、-N(R 23 )C(O)N(R 24 )-、-C(O)O-、-OC(O)-、-N(R 23 )C(O)O-、-OC(O)N(R 24 )-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-、-OP(S)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N-、-OP(S)(NR 23 R 24 )-N-、-OP(O)(NR 23 R 24 )-O-、-OP(S)(NR 23 R 24 )-O-、-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R 24 )-O-、-P(S)(NR 23 R 24 )-O-, -SS-, substituted (eg, substituted with a substituent, a size-restricted substituent, or a lower substituent) alkylene (eg, C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 3 are independently a bond, a bond, -N(R 23 )-, -O-, -S-, -C(O)-, -N(R 23 )C(O)-、-C(O)N(R 24 )-、-N(R 23 )C(O)N(R 24 )-、-C(O)O-、-OC(O)-、-N(R 23 )C(O)O-、-OC(O)N(R 24 )-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-、-OP(S)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N-、-OP(S)(NR 23 R 24 )-N-、-OP(O)(NR 23 R 24 )-O-、-OP(S)(NR 23 R 24 )-O-、-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R 24 )-O-、-P(S)(NR 23 R 24 )-O-, -SS-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 3 When replaced, L 3 In the embodiment, when L 3 When replaced, L 3 is substituted with a size-restricted substituent. In an embodiment, when L 3 When replaced, L 3 Substituted with a lower substituent.

[0250] L 4 are independently a bond, a bond, -N(R 23 )-, -O-, -S-, -C(O)-, -N(R 23 )C(O)-、-C(O)N(R 24 )-、-N(R 23 )C(O)N(R 24 )-、-C(O)O-、-OC(O)-、-N(R 23 )C(O)O-、-OC(O)N(R 24 )-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-,-OP(S)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N-、-OP(S)(NR 23 R 24 )-N-、-OP(O)(NR 23 R 24 )-O-、-OP(S)(NR 23 R 24 )-O-、-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R24 )-O-、-P(S)(NR 23 R 24 )-O-, -SS-, substituted (eg, substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted alkylene (eg, C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 4 It is a bond, a bond, -N(R 23 )-, -O-, -S-, -C(O)-, -N(R 23 )C(O)-、-C(O)N(R 24 )-、-N(R 23 )C(O)N(R 24 )-、-C(O)O-、-OC(O)-、-N(R 23 )C(O)O-、-OC(O)N(R 24 )-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-、-OP(S)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N-、-OP(S)(NR 23 R 24 )-N-、-OP(O)(NR 23 R 24 )-O-、-OP(S)(NR 23 R24 )-O-、-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R 24 )-O-、-P(S)(NR 23 R 24 )-O-, -SS-, substituted (eg, substituted with a substituent, a size-restricted substituent, or a lower substituent) alkylene (eg, C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 4 It is a bond, a bond, -N(R 23 )-, -O-, -S-, -C(O)-, -N(R 23 )C(O)-、-C(O)N(R 24 )-、-N(R 23 )C(O)N(R 24 )-、-C(O)O-、-OC(O)-、-N(R 23 )C(O)O-、-OC(O)N(R 24 )-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-、-OP(S)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N-、-OP(S)(NR23 R 24 )-N-、-OP(O)(NR 23 R 24 )-O-、-OP(S)(NR 23 R 24 )-O-、-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R 24 )-O-、-P(S)(NR 23 R 24 )-O-, -SS-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 4 When replaced, L 4 In the embodiment, when L 4 When replaced, L 4 is substituted with a size-restricted substituent. In an embodiment, when L 4 When replaced, L 4 Substituted with a lower substituent.

[0251] R 23 are independently hydrogen or unsubstituted alkyl (e.g., C1-C 23 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 23 are independently hydrogen. In an embodiment, R 23 are independently unsubstituted C1-C 23 In an embodiment, R 23 are independently hydrogen or unsubstituted C1-C 12 In an embodiment, R 23are independently hydrogen or unsubstituted C1-C 10 In an embodiment, R 23 is independently hydrogen or unsubstituted C1-C8 alkyl. 23 are independently hydrogen or unsubstituted C1-C6 alkyl. 23 are independently hydrogen or unsubstituted C1-C4 alkyl. 23 are independently hydrogen or unsubstituted C1-C2 alkyl.

[0252] R 24 are independently hydrogen or unsubstituted alkyl (e.g., C1-C 23 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 24 are independently hydrogen. In an embodiment, R 24 are independently unsubstituted C1-C 23 In an embodiment, R 24 are independently hydrogen or unsubstituted C1-C 12 In an embodiment, R 24 are independently hydrogen or unsubstituted C1-C 10 In an embodiment, R 24 is independently hydrogen or unsubstituted C1-C8 alkyl. 24 are independently hydrogen or unsubstituted C1-C6 alkyl. 24 are independently hydrogen or unsubstituted C1-C4 alkyl. 24 are independently hydrogen or unsubstituted C1-C2 alkyl.

[0253] R 25 are independently hydrogen or unsubstituted alkyl (e.g., C1-C 23 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 25 are independently hydrogen. In an embodiment, R 25 are independently unsubstituted C1-C 23 In an embodiment, R 25 are independently hydrogen or unsubstituted C1-C 12 In an embodiment, R 25 are independently hydrogen or unsubstituted C1-C 10 In an embodiment, R 25 is independently hydrogen or unsubstituted C1-C8 alkyl. 25 are independently hydrogen or unsubstituted C1-C6 alkyl.25 are independently hydrogen or unsubstituted C1-C4 alkyl. 25 are independently hydrogen or unsubstituted C1-C2 alkyl.

[0254] L 5 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 5 When replaced, L 5 In the embodiment, when L 5 When replaced, L 5 is substituted with a size-restricted substituent. In an embodiment, when L 5 When replaced, L 5 Substituted with a lower substituent.

[0255] L 5A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5Ais a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 5A When replaced, L 5A In the embodiment, when L 5A When replaced, L 5A is substituted with a size-restricted substituent. In an embodiment, when L 5A When replaced, L 5A Substituted with a lower substituent.

[0256] L 5B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 5B When replaced, L 5B In the embodiment, when L 5B When replaced, L 5B is substituted with a size-restricted substituent. In an embodiment, when L 5B When replaced, L 5B Substituted with a lower substituent.

[0257] L 5C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 5C When replaced, L 5C In the embodiment, when L 5C When replaced, L 5C is substituted with a size-restricted substituent. In an embodiment, when L 5C When replaced, L 5C Substituted with a lower substituent.

[0258] L 5D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 5D When replaced, L 5D In the embodiment, when L 5D When replaced, L 5D is substituted with a size-restricted substituent. In an embodiment, when L 5D When replaced, L 5D Substituted with a lower substituent.

[0259] L 5Eis a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 5E When replaced, L 5E In the embodiment, when L 5E When replaced, L 5E is substituted with a size-restricted substituent. In an embodiment, when L 5E When replaced, L 5E Substituted with a lower substituent.

[0260] L 6 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 6 When replaced, L 6 In the embodiment, when L 6 When replaced, L 6 is substituted with a size-restricted substituent. In an embodiment, when L 6 When replaced, L 6 Substituted with a lower substituent.

[0261] L 6A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 6A When replaced, L 6A In the embodiment, when L 6A When replaced, L 6A is substituted with a size-restricted substituent. In an embodiment, when L 6A When replaced, L 6A Substituted with a lower substituent.

[0262] L 6B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 6B When replaced, L 6B In the embodiment, when L 6B When replaced, L 6B is substituted with a size-restricted substituent. In an embodiment, when L 6B When replaced, L 6B Substituted with a lower substituent.

[0263] L 6C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 6C When replaced, L 6C In the embodiment, when L 6C When replaced, L 6C is substituted with a size-restricted substituent. In an embodiment, when L 6C When replaced, L 6C Substituted with a lower substituent.

[0264] L 6Dis a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 6D When replaced, L 6D In the embodiment, when L 6D When replaced, L 6D is substituted with a size-restricted substituent. In an embodiment, when L 6D When replaced, L 6D Substituted with a lower substituent.

[0265] L 6E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6Eis a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, when L 6E When replaced, L 6E In the embodiment, when L 6E When replaced, L 6E is substituted with a size-restricted substituent. In an embodiment, when L 6E When replaced, L 6E Substituted with a lower substituent.

[0266] In an embodiment, L 7 are independently substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 is independently substituted (eg, substituted with a substituent, a size-restricted substituent, or a lower substituent) alkylene (eg, C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0267] In an embodiment, L 7is independently substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 10 members, 2 to 8 members, 2 to 6 members, or 2 to 4 members). In embodiments, L 7 is independently substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 10 members, 2 to 8 members, 2 to 6 members, or 2 to 4 members). In embodiments, L 7 is independently unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroalkenylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). In embodiments, L 7 is independently substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroalkenylene (e.g., 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 membered). In embodiments, L 7 is independently unsubstituted heteroalkenylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 When replaced, L 7 In the embodiment, when L 7 When replaced, L 7 is substituted with a size-restricted substituent. In an embodiment, when L 7 When replaced, L 7 Substituted with a lower substituent.

[0268] In an embodiment, R 1 is an unsubstituted alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 is an unsubstituted C1-C 25 In an embodiment, R 1 is an unsubstituted C1-C 20 In an embodiment, R 1 is an unsubstituted C1-C 12 In an embodiment, R 1 is an unsubstituted C1-C8 alkyl. 1is an unsubstituted C1-C6 alkyl. 1 is an unsubstituted C1-C4 alkyl group. 1 It is an unsubstituted C1-C2 alkyl group.

[0269] In an embodiment, R 1 is an unsubstituted branched alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted branched C1-C 25 In an embodiment, R 1 It is an unsubstituted branched C1-C 20 In an embodiment, R 1 It is an unsubstituted branched C1-C 12 In an embodiment, R 1 is an unsubstituted branched C1-C8 alkyl group. 1 is an unsubstituted branched C1-C6 alkyl group. 1 is an unsubstituted branched C1-C4 alkyl group. 1 It is an unsubstituted branched C1-C2 alkyl group.

[0270] In an embodiment, R 1 is an unsubstituted unbranched alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted unbranched C1-C 25 In an embodiment, R 1 It is an unsubstituted unbranched C1-C 20 In an embodiment, R 1 It is an unsubstituted unbranched C1-C 12 In an embodiment, R 1 is an unsubstituted unbranched C1-C8 alkyl group. 1 is an unsubstituted unbranched C1-C6 alkyl group. 1 is an unsubstituted unbranched C1-C4 alkyl group. 1 It is an unsubstituted unbranched C1-C2 alkyl group.

[0271] In an embodiment, R 1 is an unsubstituted branched saturated alkyl group (e.g., C1-C 25、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted branched saturated C1-C 25 In an embodiment, R 1 It is an unsubstituted branched saturated C1-C 20 In an embodiment, R 1 It is an unsubstituted branched saturated C1-C 12 In an embodiment, R 1 is an unsubstituted branched saturated C1-C8 alkyl group. 1 is an unsubstituted branched saturated C1-C6 alkyl group. 1 is an unsubstituted branched saturated C1-C4 alkyl group. 1 It is an unsubstituted branched saturated C1-C2 alkyl group.

[0272] In an embodiment, R 1 is an unsubstituted branched unsaturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted branched unsaturated C1-C 25 In an embodiment, R 1 It is an unsubstituted branched unsaturated C1-C 20 In an embodiment, R 1 It is an unsubstituted branched unsaturated C1-C 12 In an embodiment, R 1 is an unsubstituted branched unsaturated C1-C8 alkyl group. 1 is an unsubstituted branched unsaturated C1-C6 alkyl group. 1 is an unsubstituted branched unsaturated C1-C4 alkyl group. 1 It is an unsubstituted branched saturated C1-C2 alkyl group.

[0273] In an embodiment, R 1 is an unsubstituted unbranched saturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted unbranched saturated C1-C 25 In an embodiment, R1 It is an unsubstituted unbranched saturated C1-C 20 In an embodiment, R 1 It is an unsubstituted unbranched saturated C1-C 12 In an embodiment, R 1 is an unsubstituted, unbranched, saturated C1-C8 alkyl group. 1 is an unsubstituted, unbranched, saturated C1-C6 alkyl group. 1 is an unsubstituted, unbranched, saturated C1-C4 alkyl group. 1 It is an unsubstituted unbranched saturated C1-C2 alkyl group.

[0274] In an embodiment, R 1 is an unsubstituted unbranched unsaturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C1-C 25 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C1-C 20 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C1-C 12 In an embodiment, R 1 is an unsubstituted unbranched unsaturated C1-C8 alkyl group. 1 is an unsubstituted unbranched unsaturated C1-C6 alkyl group. 1 is an unsubstituted unbranched unsaturated C1-C4 alkyl group. 1 It is an unsubstituted unbranched unsaturated C1-C2 alkyl group.

[0275] In an embodiment, R 1 is unsubstituted C9-C 19 In an embodiment, R 1 It is an unsubstituted branched C9-C 19 In an embodiment, R 1 It is an unsubstituted unbranched C9-C 19 In an embodiment, R 1 It is an unsubstituted branched saturated C9-C 19 In an embodiment, R 1 It is an unsubstituted branched unsaturated C9-C 19 In an embodiment, R 1 It is an unsubstituted unbranched saturated C9-C19 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C9-C 19 alkyl.

[0276] In an embodiment, R 2 is an unsubstituted alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 is an unsubstituted C1-C 25 In an embodiment, R 2 is an unsubstituted C1-C 20 In an embodiment, R 2 is an unsubstituted C1-C 12 In an embodiment, R 2 is an unsubstituted C1-C8 alkyl. 2 is an unsubstituted C1-C6 alkyl. 2 is an unsubstituted C1-C4 alkyl group. 2 It is an unsubstituted C1-C2 alkyl group.

[0277] In an embodiment, R 2 is an unsubstituted branched alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 It is an unsubstituted branched C1-C 25 In an embodiment, R 2 It is an unsubstituted branched C1-C 20 In an embodiment, R 2 It is an unsubstituted branched C1-C 12 In an embodiment, R 2 is an unsubstituted branched C1-C8 alkyl group. 2 is an unsubstituted branched C1-C6 alkyl group. 2 is an unsubstituted branched C1-C4 alkyl group. 2 It is an unsubstituted branched C1-C2 alkyl group.

[0278] In an embodiment, R 2 is an unsubstituted unbranched alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 It is an unsubstituted unbranched C1-C 25 In an embodiment, R 2 It is an unsubstituted unbranched C1-C 20 In an embodiment, R 2 It is an unsubstituted unbranched C1-C 12 In an embodiment, R 2 is an unsubstituted unbranched C1-C8 alkyl group. 2 is an unsubstituted unbranched C1-C6 alkyl group. 2 is an unsubstituted unbranched C1-C4 alkyl group. 2 It is an unsubstituted unbranched C1-C2 alkyl group.

[0279] In an embodiment, R 2 is an unsubstituted branched saturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 It is an unsubstituted branched saturated C1-C 25 In an embodiment, R 2 It is an unsubstituted branched saturated C1-C 20 In an embodiment, R 2 It is an unsubstituted branched saturated C1-C 12 In an embodiment, R 2 is an unsubstituted branched saturated C1-C8 alkyl group. 2 is an unsubstituted branched saturated C1-C6 alkyl group. 2 is an unsubstituted branched saturated C1-C4 alkyl group. 2 It is an unsubstituted branched saturated C1-C2 alkyl group.

[0280] In an embodiment, R 2 is an unsubstituted branched unsaturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 It is an unsubstituted branched unsaturated C1-C 25 In an embodiment, R 2 It is an unsubstituted branched unsaturated C1-C 20 In an embodiment, R2 It is an unsubstituted branched unsaturated C1-C 12 In an embodiment, R 2 is an unsubstituted branched unsaturated C1-C8 alkyl group. 2 is an unsubstituted branched unsaturated C1-C6 alkyl group. 2 is an unsubstituted branched unsaturated C1-C4 alkyl group. 2 It is an unsubstituted branched saturated C1-C2 alkyl group.

[0281] In an embodiment, R 2 is an unsubstituted unbranched saturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 It is an unsubstituted unbranched saturated C1-C 25 In an embodiment, R 2 It is an unsubstituted unbranched saturated C1-C 20 In an embodiment, R 2 It is an unsubstituted unbranched saturated C1-C 12 In an embodiment, R 2 is an unsubstituted, unbranched, saturated C1-C8 alkyl group. 2 is an unsubstituted, unbranched, saturated C1-C6 alkyl group. 2 is an unsubstituted, unbranched, saturated C1-C4 alkyl group. 2 It is an unsubstituted unbranched saturated C1-C2 alkyl group.

[0282] In an embodiment, R 2 is an unsubstituted unbranched unsaturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C1-C 25 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C1-C 20 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C1-C 12 In an embodiment, R 2 is an unsubstituted unbranched unsaturated C1-C8 alkyl group. 2is an unsubstituted unbranched unsaturated C1-C6 alkyl group. 2 is an unsubstituted unbranched unsaturated C1-C4 alkyl group. 2 It is an unsubstituted unbranched unsaturated C1-C2 alkyl group.

[0283] In an embodiment, R 2 is unsubstituted C9-C 19 In an embodiment, R 2 It is an unsubstituted branched C9-C 19 In an embodiment, R 2 It is an unsubstituted unbranched C9-C 19 In an embodiment, R 2 It is an unsubstituted branched saturated C9-C 19 In an embodiment, R 2 It is an unsubstituted branched unsaturated C9-C 19 In an embodiment, R 2 It is an unsubstituted unbranched saturated C9-C 19 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C9-C 19 alkyl.

[0284] In an embodiment, R 3 is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted alkyl (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heteroalkyl (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted cycloalkyl (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted heterocycloalkyl (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) or unsubstituted aryl (e.g., C6-C 12 、C6-C10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) or unsubstituted heteroaryl (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, R 3 is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, substituted (e.g., substituted with a substituent, a substituent of limited size, or a lower substituent) alkyl (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heteroalkyl (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) cycloalkyl (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) heterocycloalkyl (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent, a substituent of limited size or a lower substituent) aryl (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent, a size-restricted substituent, or a lower substituent) heteroaryl (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, R 3 is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, unsubstituted alkyl (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkyl (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), unsubstituted aryl (e.g., C6-C 12 、C6-C10 or phenyl) or unsubstituted heteroaryl (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when R 3 When replaced, R 3 In an embodiment, when R 3 When replaced, R 3 In an embodiment, when R 3 When replaced, R 3 Substituted with a lower substituent (such as oxo).

[0285] In an embodiment, the compound comprising a single-stranded oligonucleotide comprises a motif (e.g., Formula (IV) or (IV-a)) described above, including in any aspect, embodiment, claim, figure, table (e.g., Tables 1 to 5 and A to O), example, or scheme (e.g., Schemes I, II, III, and IV).

[0286] In an embodiment, the uptake domain is represented by the following structure:

[0287] R 1 、R 2 、R 3 , L 5 and L 6 As described above.

[0288] In embodiments, compounds comprising single-stranded oligonucleotides comprise one or more uptake domains having a structure as shown in Table 1 below. In embodiments, compounds comprising single-stranded oligonucleotides comprise the DTx-01-01 domain in Table 1. In embodiments, compounds comprising single-stranded oligonucleotides comprise the DTx-01-03 domain in Table 1. In embodiments, compounds comprising single-stranded oligonucleotides comprise the DTx-01-06 domain in Table 1. In embodiments, compounds comprising single-stranded oligonucleotides comprise the DTx-01-08 domain in Table 1. In embodiments, compounds comprising single-stranded oligonucleotides comprise the DTx-01-11 domain in Table 1. In embodiments, compounds comprising single-stranded oligonucleotides comprise the DTx-01-13 domain in Table 1. In embodiments, compounds comprising single-stranded oligonucleotides comprise the DTx-01-30 domain in Table 1. In embodiments, compounds comprising single-stranded oligonucleotides comprise the DTx-01-31 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-32 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-33 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-34 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-35 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-36 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-39 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-43 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-44 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-45 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-46 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-50 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-51 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-52 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-53 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-54 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-55 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-03-06 domain in Table 1.In an embodiment, the compound comprising a single-stranded oligonucleotide comprises a DTx-03-50 domain in Table 1. In an embodiment, the compound comprising a single-stranded oligonucleotide comprises a DTx-03-51 domain in Table 1. In an embodiment, the compound comprising a single-stranded oligonucleotide comprises a DTx-03-52 domain in Table 1. In an embodiment, the compound comprising a single-stranded oligonucleotide comprises a DTx-03-53 domain in Table 1. In an embodiment, the compound comprising a single-stranded oligonucleotide comprises a DTx-03-54 domain in Table 1. In an embodiment, the compound comprising a single-stranded oligonucleotide comprises a DTx-03-55 domain in Table 1. In an embodiment, the compound comprising a single-stranded oligonucleotide comprises a DTx-04-01 domain in Table 1. In an embodiment, the compound comprising a single-stranded oligonucleotide comprises a DTx-05-01 domain in Table 1. In an embodiment, the compound comprising a single-stranded oligonucleotide comprises a DTx-06-06 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-06-50 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-06-51 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-06-52 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-06-53 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-06-54 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-06-55 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-08-01 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-09-01 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-10-01 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-11-01 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-60 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-61 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-62 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-63 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-64 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-65 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-66 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-67 domain in Table 1.In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-68 domain from Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-69 domain from Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-70 domain from Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-71 domain from Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-72 domain from Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-73 domain from Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-74 domain from Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-75 domain from Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-76 domain from Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-77 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-78 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-79 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-80 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-81 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-82 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-83 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-84 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-85 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-86 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-87 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-88 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-89 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-90 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-91 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-92 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-93 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-94 domain in Table 1.In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-95 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-96 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-97 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-98 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-99 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-100 domain in Table 1. In embodiments, the compound comprising a single-stranded oligonucleotide comprises a DTx-01-101 domain in Table 1.

[0289] Table 1: Uptake Domains

[0290]

[0291]

[0292]

[0293]

[0294]

[0295]

[0296]

[0297]

[0298]

[0299]

[0300]

[0301]

[0302] In an embodiment, a single-stranded oligonucleotide comprises one or more modified nucleotides. In an embodiment, an oligonucleotide comprises one or more modified nucleotides. In an embodiment, a modified nucleotide comprises a modified sugar moiety. In an embodiment, a modified nucleotide comprises a modified internucleotide bond. In an embodiment, a modified nucleotide comprises a modified nucleobase. In an embodiment, a modified nucleotide comprises a modified 5'-terminal phosphate group. In an embodiment, a modified nucleotide comprises a modification at the 5' carbon of a pentofuranosyl sugar. In an embodiment, a modified nucleotide comprises a modification at the 3' carbon of a pentofuranosyl sugar. In an embodiment, a modified nucleotide comprises a modification at the 2' carbon of a pentofuranosyl sugar.

[0303] In an embodiment, a single-stranded oligonucleotide includes one or more modified sugar moieties. In an embodiment, an oligonucleotide includes one or more modified sugar moieties. In an embodiment, the modified sugar moiety includes a 2'-modification, i.e., relative to the 2'-OH of naturally occurring RNA or the 2'-H of DNA, the sugar moiety is modified at the 2' carbon of the pentofuranosyl sugar. In an embodiment, the 2'-modification is selected from 2'-fluoro, 2'-OCF3, 2'-O-CH3 (also referred to as "2'-OMe" or "2'-O-methyl"), 2'-OCH2CH2OCH3 (also referred to as "2'-O-methoxyethyl" or "2'-MOE"), 2'-O(CH2)2SCH3, O-(CH2)2-ON(CH3)2, -O(CH2)2O(CH2)2N(CH3)2 and -O-CH2-C(=O)-N(H)CH3. In an embodiment, the 2' modification is a 2'-fluoro modification. In embodiments, the 2' modification is a 2'-O-methyl modification. In embodiments, the 2' modification is a 2'-O-methoxyethyl modification.

[0304] In an embodiment, 2' modification is a dicyclo sugar modification, in which ribose has a covalent bond between 2' and 4' carbon. The nucleotides comprising the sugar moieties of this type of modification can be referred to as " dicyclo nucleic acids " or " BNA". In an embodiment, the covalent bond of a dicyclo sugar modification is 4'-CH2-O-2' bond (methyleneoxy), also referred to as " LNA". In an embodiment, the covalent bond of a dicyclo sugar modification is 4'-(CH2)2-O-2' bond (ethyleneoxy), also referred to as "ENA". In an embodiment, the covalent bond of a dicyclo sugar modification is 4'-CH (CH3)-O-2' bond (methyl (methyleneoxy)), also referred to as " constrained ethyl" or "cEt". In an embodiment, the covalent bond of a dicyclo sugar modification is 4'-CH (CH2-OMe)-O-2' bond, also referred to as "c-MOE". In an embodiment, the covalent bond of a dicyclo sugar modification is 4'-CH2-N (CH3)-O-2' bond. In an embodiment, the covalent bond of the dicyclic sugar modification is 4'-CH2-N (H)-O-2' bond. In an embodiment, the dicyclic sugar modification is the D sugar of α configuration. In some such embodiments, the dicyclic sugar modification is the D sugar of β configuration. In some such embodiments, the dicyclic sugar modification is the L sugar of α configuration. In some such embodiments, the dicyclic sugar modification is the L sugar of β configuration.

[0305] In embodiments, the modified sugar moiety is an acyclic nucleoside derivative lacking a bond between the 2' and 3' carbons of the sugar ring, also known as an "unlocked sugar modification."

[0306] In embodiments, the modified sugar moiety is a morpholino moiety, wherein the pentofuranosyl sugar is replaced with a six-membered methylenemorpholine ring.

[0307] In an embodiment, the modified nucleotide comprises a modification at the 6' carbon of the morpholino moiety. In an embodiment, the modified nucleotide comprises a modification at the 3' nitrogen of the morpholino moiety. In an embodiment, the modified nucleotide comprises a modification at the 2' carbon of the morpholino moiety.

[0308] In embodiments, the oxygen of the pentofuranosyl sugar is replaced with sulfur to form a thiosugar. In embodiments, the thiosugar is modified at the 2' carbon.

[0309] In embodiments, the modified sugar moiety is a hexitol nucleic acid moiety wherein the pentofuranosyl sugar is replaced with a six-membered anhydrohexitol ring. In embodiments, the hexitol nucleotide is modified at the 3' position.

[0310] In an embodiment, a single-stranded oligonucleotide comprises one or more modified internucleotide bonds. In an embodiment, an oligonucleotide comprises one or more modified internucleotide bonds. In an embodiment, the modified internucleotide bond is a phosphorothioate bond. In an embodiment, the modified internucleotide bond is a phosphorodiamidate bond. In an embodiment, the modified internucleotide bond is a methylphosphonate internucleotide bond. In an embodiment, the modified internucleotide bond is a borane phosphate bond. In an embodiment, the modified internucleotide bond is an O-methylphosphoamido bond. In an embodiment, the modified internucleotide bond is a phosphoramidoester bond. In an embodiment, the single-stranded oligonucleotide contains a positive backbone. In an embodiment, the single-stranded oligonucleotide contains a non-ionic backbone.

[0311] In an embodiment, the single-stranded oligonucleotide comprises one or more modified nucleobases. In an embodiment, the oligonucleotide comprises one or more modified nucleobases. In an embodiment, the modified nucleobase is selected from 5-hydroxymethylcytosine, 7-deazaguanine and 7-deazaadenine. In an embodiment, the modified nucleobase is selected from 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. In an embodiment, the modified nucleobase is selected from 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.

[0312] In embodiments, the single-stranded oligonucleotide induces exon skipping of dystrophin pre-mRNA. In embodiments, the single-stranded oligonucleotide induces exon skipping of dystrophin pre-mRNA. In embodiments, the single-stranded oligonucleotide induces exon skipping of dystrophin pre-mRNA. In embodiments, the single-stranded oligonucleotide induces exon skipping of dystrophin pre-mRNA. In embodiments, the single-stranded oligonucleotide induces exon skipping of dystrophin pre-mRNA.

[0313] In embodiments, the nucleobase sequence of the single-stranded oligonucleotide is complementary to a splice donor site, a splice acceptor site, an exonic splicing enhancer (ESE), a splice branch point, an exon recognition sequence, or a splicing enhancer of dystrophin pre-mRNA.

[0314] In embodiments, the nucleobase sequence of the single-stranded oligonucleotide is complementary to an annealing site of the dystrophin pre-mRNA. Certain annealing sites and nucleobase sequences are provided in Table 2. In embodiments, the annealing site is selected from any one of the annealing sites in Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide is selected from any one of the nucleobase sequences in Table 2.

[0315] In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 8 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 9 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 10 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 11 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 12 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 13 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 14 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 15 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 16 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 17 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 18 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 19 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 20 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 21 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 22 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 23 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 24 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 25 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 26 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 27 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single-stranded oligonucleotide comprises at least 28 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single stranded oligonucleotide comprises at least 29 consecutive nucleobases selected from the nucleobase sequences of Table 2. In embodiments, the nucleobase sequence of the single stranded oligonucleotide comprises at least 30 consecutive nucleobases selected from the nucleobase sequences of Table 2.

[0316] Table 2: Annealing sites and nucleobase sequences targeting dystrophin

[0317]

[0318]

[0319]

[0320]

[0321]

[0322]

[0323] In an embodiment, the annealing site is H51A (+66+95), which is a site of nucleotides 66 to 95 starting from exon 51 of human dystrophin pre-mRNA. In an embodiment, the annealing site is H53A (+36+60), which is a site of nucleotides 36 to 60 starting from exon 53 of human dystrophin pre-mRNA. In an embodiment, the annealing site is H45A (-03+19), which is a site from the last 3 nucleotides of the intron before exon 45 of human dystrophin pre-mRNA to the 19th nucleotide of exon 45. In an embodiment, the annealing site is H51A (+68+87), which is a site of nucleotides 68 to 87 starting from exon 51 of human dystrophin pre-mRNA. In an embodiment, the annealing site is H53A (+36+56), which is a site from the 36th to the 56th nucleotides from exon 53 of human dystrophin pre-mRNA. In an embodiment, the annealing site is H45A (-10+8), which is a site from the last 10 nucleotides of the intron before exon 45 of human dystrophin pre-mRNA to the 8th nucleotide from exon 45.

[0324] In an embodiment, the nucleobase sequence of the single-stranded oligonucleotide is 5'-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3' (SEQ ID NO: 1). In an embodiment, the nucleobase sequence of the single-stranded oligonucleotide is 5'-GUUGCCUCCGGUUCUGAAGGUGUUC-3' (SEQ ID NO: 2). In an embodiment, the nucleobase sequence of the single-stranded oligonucleotide is 5'-CAATGCCATCCTGGAGTTCCTG-3' (SEQ ID NO: 3). In an embodiment, the nucleobase sequence of the single-stranded oligonucleotide is 5'-UCAAGGAAGAUGGCAUUUCU-3' (SEQ ID NO: 4). In an embodiment, the nucleobase sequence of the single-stranded oligonucleotide is 5'-CGCTGCCCAATGCCAUCC-3' (SEQ ID NO: 5). In an embodiment, the nucleobase sequence of the single-stranded oligonucleotide is 5'-CCTCCGGTTCTGAAGGTGTTC-3' (SEQ ID NO: 6).

[0325] In an embodiment, the single stranded oligonucleotide is 8 to 30 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 10 to 30 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 15 to 30 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 20 to 30 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 25 to 30 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 8 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 8 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 9 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 10 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 11 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 12 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 13 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 14 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 15 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 16 nucleotides in length. In an embodiment, the single stranded oligonucleotide is 17 nucleotides in length. In an embodiment, the length of the single stranded oligonucleotide is 18 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 19 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 20 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 21 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 22 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 23 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 24 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 25 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 26 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 27 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 28 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 29 nucleotides. In an embodiment, the length of the single stranded oligonucleotide is 30 nucleotides.

[0326] In an embodiment, the single stranded oligonucleotide comprises one or more sugar moieties independently selected from 2'-O-methyl sugar modifications, 2'-O-methoxyethyl sugar modifications and 2'-fluoro sugar modifications. In an embodiment, the single stranded oligonucleotide comprises one or more sugar moieties independently selected from 2'-O-methyl sugar modifications and 2'-O-methoxyethyl sugar modifications. In an embodiment, each nucleotide of the single stranded oligonucleotide comprises a sugar moiety independently selected from 2'-O-methyl sugar modifications, 2'-O-methoxyethyl sugar modifications and 2'-fluoro sugar modifications. In an embodiment, each nucleotide of the single stranded oligonucleotide comprises a sugar moiety independently selected from 2'-O-methyl sugar modifications and 2'-O-methoxyethyl sugar modifications.

[0327] In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3' (SEQ ID NO:1), each Nucleotide comprises morpholino moiety, and each morpholino moiety is connected by diaminophosphoester bond.In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3' (SEQ ID NO:1), each Nucleotide of single stranded oligonucleotide comprises 2'-O-methoxyethyl sugar modification, and wherein between each Nucleotide, bond is thiophosphate bond.In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3' (SEQ ID NO:1), each Nucleotide of single stranded oligonucleotide comprises 2'-O-methyl sugar modification, and wherein between each Nucleotide, bond is thiophosphate bond.

[0328] In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-GUUGCCUCCGGUUCUGAAGGUGUUC-3' (SEQ ID NO:2), each Nucleotide comprises morpholino moiety, and each morpholino moiety is connected by diaminophosphoester bond.In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-GUUGCCUCCGGUUCUGAAGGUGUUC-3' (SEQID NO:2), each Nucleotide of single stranded oligonucleotide comprises 2'-O-methoxyethyl sugar modification, and wherein between each Nucleotide, bond is thiophosphate bond.In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-GUUGCCUCCGGUUCUGAAGGUGUUC-3' (SEQ ID NO:2), each Nucleotide of single stranded oligonucleotide comprises 2'-O-methyl sugar modification, and wherein between each Nucleotide, bond is thiophosphate bond.

[0329] In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-CAATGCCATCCTGGAGTTCCTG-3' (SEQ ID NO:3), each Nucleotide includes morpholino moiety, and each morpholino moiety is connected by diaminophosphoester bond.In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-CAATGCCATCCTGGAGTTCCTG-3' (SEQ ID NO:3), each Nucleotide of single stranded oligonucleotide includes 2'-O-methoxyethyl sugar modification, and wherein between each Nucleotide, bond is thiophosphate bond.In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-CAATGCCATCCTGGAGTTCCTG-3' (SEQ ID NO:3), each Nucleotide of single stranded oligonucleotide includes 2'-O-methyl sugar modification, and wherein between each Nucleotide, bond is thiophosphate bond.

[0330] In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-UCAAGGAAGAUGGCAUUUCU-3' (SEQ ID NO:4), each Nucleotide comprises morpholino moiety, and each morpholino moiety is connected by diaminophosphoester bond.In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-UCAAGGAAGAUGGCAUUUCU-3' (SEQ ID NO:4), each Nucleotide of single stranded oligonucleotide comprises 2'-O-methoxyethyl sugar modification, and wherein between each Nucleotide, bond is thiophosphate bond.In an embodiment, the core base sequence of single stranded oligonucleotide is 5'-UCAAGGAAGAUGGCAUUUCU-3' (SEQ ID NO:4), each Nucleotide of single stranded oligonucleotide comprises 2'-O-methyl sugar modification, and wherein between each Nucleotide, bond is thiophosphate bond.

[0331] In an embodiment, the nucleobase sequence of the single-stranded oligonucleotide is 5'-CGCTGCCCAATGCCAUCC-3' (SEQ ID NO: 5), and each nucleotide of the single-stranded oligonucleotide comprises a 2' modification, wherein the 2' modification is a 2'-O-methyl modification or a bicyclic sugar modification having a 4'-(CH2)2-O-2' bond, and wherein each bond is a phosphodiester bond.

[0332] In an embodiment, the nucleobase sequence of the single-stranded oligonucleotide is 5'-UCAAGGAAGAUGGCAUUUCU-3' (SEQ ID NO: 4), each nucleotide of the single-stranded oligonucleotide comprises a 2'-modification, wherein the 2' modification is a 2'-O-methyl modification or a 2'-fluoro modification, and wherein each internucleotide bond is selected from a phosphorothioate bond and a phosphodiester bond in the Sp conformation.

[0333] In an embodiment, the nucleobase sequence of the single-stranded oligonucleotide is 5'-CCTCCGGTTCTGAAGGTGTTC-3' (SEQ ID NO: 6), each nucleotide comprises a morpholino moiety, and each morpholino moiety is linked by a phosphorodiamidate bond.

[0334] Certain single-stranded oligonucleotide structures are provided in Table 4, wherein each nucleotide is described by the "Nsl" notation, where N=nucleobase, s=sugar, and l=internucleotide linker. The 5' and 3' ends of each oligonucleotide are also shown. Descriptions of each sugar, linker, 5' end, and 3' end abbreviations are shown in Table 3. Nucleobases are represented by A, G, T, C, U, and mC (5-methylcytosine). Single-stranded oligonucleotides conjugated to an uptake motif are shown in Table 5, wherein the uptake domain and linker are indicated.

[0335] In an embodiment, the single-stranded oligonucleotide (A) of formula (IV) is a structure provided in Table 4. In an embodiment, the compound comprising the single-stranded oligonucleotide is a structure provided in Table 5.

[0336] Table 3: Nucleotide Sugar and Bond Abbreviations

[0337]

[0338]

[0339] Table 4: Single-stranded oligonucleotides targeting dystrophin

[0340]

[0341]

[0342] Table 5: Conjugated dystrophin targeting compounds

[0343]

[0344]

[0345] In embodiments, the compound further comprises a ligand. In embodiments, the ligand may comprise one or more selected from a synthetic compound, a peptide, an antibody, a carbohydrate, or another nucleic acid. In embodiments, the ligand may comprise one or more selected from a peptide, an antibody, a carbohydrate, or another nucleic acid. In embodiments, the uptake motif independently comprises one or more selected from a peptide, an antibody, a carbohydrate, or another nucleic acid. In embodiments, one or more turnover motifs comprise one or more selected from a peptide, an antibody, a carbohydrate, or another nucleic acid. In embodiments, a ligand may replace a turnover motif. In embodiments, one or more ligands may replace one or more turnover motifs.

[0346] In embodiments, the compound further comprises a ligand. In embodiments, the ligand may comprise one or more selected from a synthetic compound, a peptide, an antibody, a carbohydrate, or another nucleic acid. In embodiments, the ligand may comprise one or more selected from a peptide, an antibody, a carbohydrate, or another nucleic acid. In embodiments, the uptake motif independently comprises one or more selected from a peptide, an antibody, a carbohydrate, or another nucleic acid. In embodiments, one or more uptake motifs comprise one or more selected from a peptide, an antibody, a carbohydrate, or another nucleic acid. In embodiments, a ligand may replace an uptake motif. In embodiments, one or more ligands may replace one or more uptake motifs.

[0347] Pharmaceutical composition

[0348] Also provided herein are pharmaceutical preparations or pharmaceutical compositions. In an embodiment, the pharmaceutical preparation (e.g., composition) comprises a compound (e.g., formula (IV) or (IV-a)) as described above in any aspect, embodiment, claim, chart (e.g., Tables 1 to 5 and A to O), example, or scheme (e.g., Scheme I, II, III, and IV), and a pharmaceutically acceptable excipient.

[0349] The pharmaceutical compositions can be prepared and administered in a variety of dosage formulations.The compounds can be administered orally, rectally, or by injection (eg, intravenously, intramuscularly, intradermally, subcutaneously, intraduodenally, or intraperitoneally).

[0350] For preparing pharmaceutical compositions from the compounds described herein, pharmaceutically acceptable carriers can be solid or liquid. Solid form formulations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances that can also act as a diluent, flavoring agent, binder, preservative, tablet disintegrant, or encapsulating material.

[0351] In powders, the carrier can be a finely divided solid which is mixed with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

[0352] Powders and tablets preferably contain 5% to 70% active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with an encapsulating material as a carrier, which provides a capsule in which the active ingredient, with or without other carriers, is surrounded by the carrier (which carrier is thus associated with it). Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0353] To prepare suppositories, a low melting point wax such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active ingredient is dispersed uniformly therein by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby solidify.

[0354] Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water / propylene glycol solutions.For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

[0355] Aqueous solutions suitable for oral use can be prepared by dissolving the active ingredient in water and adding suitable colorants, flavorings, stabilizers, and thickening agents as desired. Aqueous suspensions suitable for oral use can be prepared by dispersing the finely divided active ingredient in water with a viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

[0356] Also included are solid form preparations that are intended to be converted into liquid form preparations for oral administration shortly before use. Such liquid compositions include solutions, suspensions, and emulsions. In addition to the active ingredient, these preparations may also contain colorants, flavorings, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

[0357] Pharmaceutical formulations are preferably in unit dosage form. In such form, the formulation is subdivided into unit doses containing appropriate quantities of the active ingredient. The unit dosage form can be a packaged formulation containing discrete quantities of the formulation, such as packaged tablets, capsules, and powders in vials or ampoules. Likewise, the unit dosage form can itself be a capsule, tablet, cachet, or lozenge, or it can be the appropriate number of any of these in packaged form.

[0358] The amount of active ingredient in a unit dose of preparation may be varied or adjusted depending on the particular application and the potency of the active ingredient. If desired, the composition may also contain other compatible therapeutic agents.

[0359] Some compounds may have limited solubility in water and, therefore, may require a surfactant or other suitable cosolvent in the composition. Such cosolvents include: polysorbates 20, 60, and 80; Pluronic F-68, F-84, and P-103; cyclodextrins; and polyoxyl 35 castor oil. Such cosolvents are typically used at levels between about 0.01% and about 2% by weight. A viscosity greater than that of a simple aqueous solution may be desirable to reduce variability in formulating these formulations, to reduce physical separation of components of a suspension or emulsion of the formulation, and / or to otherwise improve the formulation. Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxypropyl cellulose, chondroitin sulfate and its salts, hyaluronic acid and its salts, and combinations of the foregoing. Such agents are typically used at levels between about 0.01% and about 2% by weight.

[0360] The pharmaceutical composition may further include components that provide sustained release and / or comfort. Such components include high molecular weight, anionic mucoid polymers, gelling polysaccharides, and finely dispersed drug carrier substrates.

[0361] The pharmaceutical composition can be intended for intravenous use. Pharmaceutically acceptable excipients may include a buffer to adjust the pH to the desired range for intravenous use. Many buffers including inorganic acid salts such as phosphates, borates, and sulfates are known.

[0362] In one aspect, a cell is provided containing a compound comprising a single-stranded oligonucleotide (A) (e.g., (IV) or (IV-a)) as described above, including in any aspect, embodiment, claim, figure, table (e.g., Tables 1 to 5 and A to O), example, or scheme (e.g., Schemes I, II, III, and IV).

[0363] In an embodiment, the cell containing the compound comprising the single-stranded oligonucleotide (A) may include but is not limited to fibroblasts, kidney cells, endothelial cells, adipocytes, neuronal cells, muscle cells, hepatocytes, T lymphocytes and B lymphocytes. In an embodiment, the cell containing the compound comprising the single-stranded oligonucleotide (A) may include but is not limited to human umbilical vein endothelial cells, NIH3T3 cells, RAW264.7 cells, HEK293 cells or SH-SY5Y cells.

[0364] Methods and uses

[0365] In one aspect, a method comprising contacting a cell with a compound described herein is provided. In embodiments, the method comprises contacting a cell with one or more compounds as described herein in any aspect, embodiment, claim, figure, table (e.g., Tables 1 to 5 and A to O), example, or scheme (e.g., Schemes I, II, III, and IV). In embodiments, the contacting occurs in vitro. In embodiments, the contacting occurs ex vivo. In embodiments, the contacting occurs in vivo.

[0366] In one aspect, a method comprising inducing exon skipping of dystrophin pre-mRNA in a cell is provided. In embodiments, the method comprises contacting the cell with one or more compounds as described herein in any aspect, embodiment, claim, figure, table (e.g., Tables 1 to 5 and A to O), example, or scheme (e.g., Schemes I, II, III, and IV). In embodiments, the contacting occurs in vitro. In embodiments, the contacting occurs ex vivo. In embodiments, the contacting occurs in vivo.

[0367] In one aspect, a method of administering a compound as described herein to a subject is provided. In an embodiment, the method comprises administering to the subject one or more compounds as described herein in any aspect, embodiment, claim, figure, table (e.g., Tables 1 to 5 and A to O), example or scheme (e.g., Scheme I, II, III and IV). In an embodiment, the subject suffers from Duchenne muscular dystrophy. In an embodiment, the subject suffers from Duchenne muscular dystrophy and is determined to have a mutation in the dystrophin gene that is suitable for exon skipping.

[0368] In one aspect, a method of treating Duchenne muscular dystrophy is provided. In an embodiment, the method comprises administering to a subject one or more compounds as described herein in any aspect, embodiment, claim, figure, table (e.g., Tables 1 to 5 and A to O), example, or scheme (e.g., Schemes I, II, III, and IV).

[0369] In embodiments involving contacting a cell, one or more exons of the pre-mRNA of dystrophin are skipped at increased levels relative to the absence of the compound. In embodiments involving administration to a subject, one or more exons of the pre-mRNA of dystrophin are skipped at increased levels relative to the absence of the compound.

[0370] In embodiments involving administration to a subject, administration is systemic administration, which may include, but is not limited to, subcutaneous administration, intravenous administration, intramuscular administration, and oral administration. In embodiments involving administration to a subject, administration is local administration, which may include, but is not limited to, intravitreal administration, intrathecal administration, and intraventricular administration.

[0371] In one aspect, there is provided a compound as described herein for use in therapy. In one aspect, there is provided a compound as described herein for use in the preparation of a medicament.

[0372] In one aspect, a method of introducing a single-stranded oligonucleotide into a cell in a subject is provided. In embodiments, the method comprises administering to the subject a compound as described herein.

[0373] Example

[0374] Example 1. Compounds having the following structure:

[0375]

[0376] in

[0377] A is a single-stranded oligonucleotide having a nucleobase sequence complementary to a portion of dystrophin pre-mRNA; t is an integer from 1 to 5;

[0378] L 3 and L 4 are independently a bond, -N(R 23 )-, -O-, -S-, -C(O)-, -N(R 23 )C(O)-、-C(O)N(R 24 )-、-N(R 23 )C(O)N(R 24 )-、-C(O)O-、-OC(O)-、-N(R 23 )C(O)O-、-OC(O)N(R 24 )-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(R 25 )-O-、-OP(S)(R 25 )-O-、-OP(O)(NR 23 R 24 )-N-、-OP(S)(NR 23 R 24 )-N-、-OP(O)(NR 23 R 24 )-O-、-OP(S)(NR 23 R 24 )-O-、-P(O)(NR 23 R 24 )-N-、-P(S)(NR 23 R 24 )-N-、-P(O)(NR 23 R 24 )-O-、-P(S)(NR23 R 24 )-O-, -SS-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;

[0379] L 5 Yes-L 5A -L 5B -L 5C -L 5D -L 5E -;

[0380] L 6 Yes-L 6A -L 6B -L 6C -L 6D -L 6E -;

[0381] R 1 and R 2 are independently unsubstituted C1-C 25 Alkyl, where R 1 and R 2 At least one of them is unsubstituted C9-C 19 alkyl;

[0382] R 3 is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

[0383] L 5A , L 5B , L 5C , L 5D , L 5E , L 6A , L 6B , L 6C , L 6D and L 6E is independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and

[0384] Each R 23 、R 24 and R 25 are independently hydrogen or unsubstituted C1-C 10 alkyl.

[0385] Embodiment 2. The compound of embodiment 1, wherein t is 1.

[0386] Embodiment 3. The compound according to embodiment 1, wherein t is 2.

[0387] Embodiment 4. The compound according to embodiment 1, wherein t is 3.

[0388] Embodiment 5. The compound according to one of embodiments 1 to 4, wherein R 23 、R 24 and R 25 Each of is independently hydrogen or unsubstituted C1-C3 alkyl.

[0389] Embodiment 6. The compound according to one of embodiments 1 to 4, wherein one L 3 Attached to the 3' carbon of the oligonucleotide.

[0390] Embodiment 7. The compound according to one of embodiments 1 to 4, wherein one L 3 Attached to the 3' nitrogen of the oligonucleotide.

[0391] Embodiment 8. The compound according to one of embodiments 1 to 4, wherein one L 3 Attached to the 5' carbon of the oligonucleotide.

[0392] Embodiment 9. The compound according to one of embodiments 1 to 4, wherein one L 3 Attached to the 6' carbon of the oligonucleotide.

[0393] Embodiment 10. The compound according to one of embodiments 1 to 4, wherein one L 3 attached to the nucleobases of the oligonucleotide.

[0394] Embodiment 11. The compound according to one of embodiments 1 to 10, wherein L 3 and L 4are independently a bond, -NH-, -O-, -C(O)-, -C(O)O-, -OC(O)-, -OPO2-O-, -OP(O)(S)-O-, -OP(O)(CH3)-O-, -OP(S)(CH3)-O-, -OP(O)(N(CH3)2)-N-, -OP(O)(N(CH3)2)-O-, -OP(S)(N(CH3)2)-N-, -OP(S)(N(CH3)2)-O-, -P(O)(N(CH3)2)-N-, -P(O)(N(CH3)2)-O-, -P(S)(N(CH3)2)-N-, -P(S)(N(CH3)2)-O-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.

[0395] Embodiment 12. The compound according to one of embodiments 1 to 11, wherein L 3 Independently

[0396] Embodiment 13. The compound according to one of embodiments 1 to 11, wherein L 3 are independently -OPO2-O- or -OP(O)(S)-O-.

[0397] Embodiment 14. The compound according to one of embodiments 1 to 11, wherein L 3 Independently is –O-.

[0398] Embodiment 15. A compound according to any one of embodiments 1 to 11, wherein L 3 are independently -C(O)-.

[0399] Embodiment 16. A compound according to any one of embodiments 1 to 11, wherein L 3 are independently -OP(O)(N(CH3)2)-N-.

[0400] Embodiment 17. A compound according to any one of embodiments 1 to 14, wherein L 4 and are independently substituted or unsubstituted alkylene or substituted or unsubstituted heteroalkylene.

[0401] Embodiment 18. A compound according to any one of embodiments 1 to 17, wherein L 4 Independently is –L 7 -NH-C(O)- or –L 7 -C(O)-NH-, where L 7 is a substituted or unsubstituted alkylene group.

[0402] Embodiment 19. The compound according to one of embodiments 1 to 18, wherein L4 Independently

[0403] Embodiment 20. The compound according to one of embodiments 1 to 18, wherein L 4 Independently

[0404] Embodiment 20. The compound according to one of embodiments 1 to 20, wherein -L 3 -L 4 -Independently is –OL 7 -NH-C(O)- or -OL 7 -C(O)-NH-, where L 7 and alkylene and alkylene are independently substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, or substituted or unsubstituted heteroalkenylene.

[0405] Embodiment 22. The compound according to embodiment 21, wherein -L 3 -L 4 -Independently is –OL 7 -NH-C(O)-, where L 7 and independently substituted or unsubstituted C5-C8 alkylene.

[0406] Embodiment 23. The compound according to embodiment 22, wherein -L 3 -L 4 - Independently

[0407] Embodiment 24. The compound according to one of embodiments 1 to 11, wherein -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-、-OP(O)(S)-OL 7 -NH-C(O)-、-OPO2-OL 7 -C(O)-NH- or –OP(O)(S)-OL 7 -C(O)-NH-, where L 7 and are independently substituted or unsubstituted alkylene.

[0408] Embodiment 25. The compound according to embodiment 24, wherein -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)- or –OP(O)(S)-OL 7 -NH-C(O)-, where L 7 and independently substituted or unsubstituted C5-C8 alkylene.

[0409] Embodiment 26. The compound according to embodiment 25, wherein -L 3 -L 4 - Independently

[0410] Embodiment 27. The compound according to embodiment 27, wherein -L 3 -L 4 - Independently and attached to the 3' carbon of the oligonucleotide.

[0411] Embodiment 28. The compound according to embodiment 26, wherein -L 3 -L 4 - Independently

[0412] and attached to the 3' nitrogen of the oligonucleotide.

[0413] Embodiment 29. The compound according to embodiment 26, wherein -L 3 -L 4 - Independently and attached to the 5' carbon of the oligonucleotide.

[0414] Embodiment 30. The compound according to embodiment 26, wherein -L 3 -L 4 - Independently and attached to the 6' carbon of the oligonucleotide.

[0415] Embodiment 31. The compound according to embodiment 26, wherein -L 3 -L 4 - Independently and attached to the nucleobases of the oligonucleotide.

[0416] Embodiment 32. The compound according to one of embodiments 1 to 31, wherein R 3 are independently hydrogen.

[0417] Embodiment 33. The compound according to one of embodiments 1 to 32, wherein L 6 are independently -NHC(O)-, -C(O)NH-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.

[0418] Embodiment 34. The compound according to embodiment 33, wherein L 6 is independently -NHC(O)-.

[0419] Embodiment 35. The compound according to embodiment 33, wherein

[0420] L 6A is independently a bond or unsubstituted alkylene;

[0421] L 6B is independently a bond, -NHC(O)-, or unsubstituted arylene;

[0422] L 6C is independently a bond, unsubstituted alkylene, or unsubstituted arylene;

[0423] L 6D is independently a bond or unsubstituted alkylene; and

[0424] L 6E is independently a bond or -NHC(O)-.

[0425] Embodiment 36. The compound according to embodiment 33, wherein

[0426] L 6A are independently a bond or unsubstituted C1-C8 alkylene;

[0427] L 6B is independently a bond, -NHC(O)-, or unsubstituted phenylene;

[0428] L 6C is independently a bond, unsubstituted C2-C8 alkynylene or unsubstituted phenylene;

[0429] L 6D are independently a bond or unsubstituted C1-C8 alkylene; and

[0430] L 6E is independently a bond or -NHC(O)-.

[0431] Embodiment 37. The compound according to one of embodiments 1 to 32, wherein L 6 independently are keys,

[0432]

[0433] Embodiment 38. The compound according to one of embodiments 1 to 37, wherein L 5 are independently -NHC(O)-, -C(O)NH-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.

[0434] Embodiment 39. The compound according to one of embodiments 1 to 37, wherein L 5 is independently -NHC(O)-.

[0435] Embodiment 40. The compound according to one of embodiments 1 to 37, wherein

[0436] L 5A is independently a bond or unsubstituted alkylene;

[0437] L 5B is independently a bond, -NHC(O)-, or unsubstituted arylene;

[0438] L 5C is independently a bond, unsubstituted alkylene, or unsubstituted arylene;

[0439] L 5D is independently a bond or unsubstituted alkylene; and

[0440] L 5E is independently a bond or -NHC(O)-.

[0441] Embodiment 41. The compound according to one of embodiments 1 to 37, wherein

[0442] L 5A are independently a bond or unsubstituted C1-C8 alkylene;

[0443] L 5B is independently a bond, -NHC(O)-, or unsubstituted phenylene;

[0444] L 5C is independently a bond, unsubstituted C2-C8 alkynylene or unsubstituted phenylene;

[0445] L 5D are independently a bond or unsubstituted C1-C8 alkylene; and

[0446] L 5E is independently a bond or -NHC(O)-.

[0447] Embodiment 42. The compound according to one of embodiments 1 to 37, wherein L 5 independently are keys,

[0448]

[0449] Embodiment 43. The compound according to one of embodiments 1 to 37, wherein R 1 is an unsubstituted C1-C 17 alkyl.

[0450] Embodiment 44. The compound according to one of embodiments 1 to 37, wherein R 1 is unsubstituted C 11 -C 17 alkyl.

[0451] Embodiment 45. The compound according to one of embodiments 1 to 37, wherein R 1 is unsubstituted C 13 -C 17 alkyl.

[0452] Embodiment 46. The compound according to one of embodiments 1 to 37, wherein R 1 is unsubstituted C 14 -C 15 alkyl.

[0453] Embodiment 47. The compound according to one of embodiments 1 to 37, wherein R 1 It is an unsubstituted unbranched C1-C 17 alkyl.

[0454] Embodiment 48. The compound according to one of embodiments 1 to 37, wherein R 1 is an unsubstituted unbranched C 11 -C 17 alkyl.

[0455] Embodiment 49. The compound according to one of embodiments 1 to 37, wherein R 1 is an unsubstituted unbranched C 13 -C 17 alkyl.

[0456] Embodiment 50. The compound according to one of embodiments 1 to 37, wherein R 1 is an unsubstituted unbranched C 14 -C 15 alkyl.

[0457] Embodiment 51. The compound according to one of embodiments 1 to 37, wherein R 1 It is an unsubstituted unbranched saturated C1-C 17 alkyl.

[0458] Embodiment 52. The compound according to one of embodiments 1 to 37, wherein R 1 is an unsubstituted unbranched saturated C 11 -C 17 alkyl.

[0459] Embodiment 53. The compound according to one of embodiments 1 to 37, wherein R 1 is an unsubstituted unbranched saturated C 13 -C 17 alkyl.

[0460] Embodiment 54. The compound according to one of embodiments 1 to 37, wherein R 1is an unsubstituted unbranched saturated C 14 -C 15 alkyl.

[0461] Embodiment 55. The compound according to one of embodiments 1 to 54, wherein R 2 is an unsubstituted C1-C 17 alkyl.

[0462] Embodiment 56. The compound according to one of embodiments 1 to 54, wherein R 2 is unsubstituted C 11 -C 17 alkyl.

[0463] Embodiment 57. The compound according to one of embodiments 1 to 54, wherein R 2 is unsubstituted C 13 -C 17 alkyl.

[0464] Embodiment 58. The compound according to one of embodiments 1 to 54, wherein R 2 is unsubstituted C 14 -C 15 alkyl.

[0465] Embodiment 59. The compound according to one of embodiments 1 to 54, wherein R 2 It is an unsubstituted unbranched C1-C 17 alkyl.

[0466] Embodiment 60. The compound according to one of embodiments 1 to 54, wherein R 2 is an unsubstituted unbranched C 11 -C 17 alkyl.

[0467] Embodiment 61. The compound according to one of embodiments 1 to 54, wherein R 2 is an unsubstituted unbranched C 13 -C 17 alkyl.

[0468] Embodiment 62. The compound according to one of embodiments 1 to 54, wherein R 2 is an unsubstituted unbranched C 14 -C 15 alkyl.

[0469] Embodiment 63. The compound according to one of embodiments 1 to 54, wherein R 2 It is an unsubstituted unbranched saturated C1-C 17 alkyl.

[0470] Embodiment 64. The compound according to one of embodiments 1 to 54, wherein R 2 is an unsubstituted unbranched saturated C 11 -C 17 alkyl.

[0471] Embodiment 65. The compound according to one of embodiments 1 to 54, wherein R 2 is an unsubstituted unbranched saturated C 13 -C 17 alkyl.

[0472] Embodiment 66. The compound according to one of embodiments 1 to 54, wherein R 2 is an unsubstituted unbranched saturated C 14 -C 15 alkyl.

[0473] Embodiment 67. The compound of one of embodiments 1 to 54, wherein the single-stranded oligonucleotide induces skipping of an exon of the dystrophin pre-mRNA.

[0474] Embodiment 68. A compound according to embodiment 67, wherein the nucleobase sequence of the single-stranded oligonucleotide is complementary to a splice donor site, a splice acceptor site, an exonic splicing enhancer (ESE), a splice branch point, an exon recognition sequence or a splicing enhancer of the dystrophin pre-mRNA.

[0475] Embodiment 69. The compound of embodiment 67, wherein the nucleobase sequence of the single-stranded oligonucleotide is complementary to an annealing site selected from Table 2.

[0476] Embodiment 70. The compound of one of embodiments 1 to 69, wherein the single-stranded oligonucleotide is 25 to 30 nucleotides in length.

[0477] Embodiment 71. The compound of one of embodiments 1 to 69, wherein the nucleobase sequence of the single-stranded oligonucleotide is selected from the nucleobase sequences in Table 2.

[0478] Embodiment 72. The compound of embodiment 71, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3' (SEQ ID NO: 1).

[0479] Embodiment 73. The compound of embodiment 71, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-GUUGCCUCCGGUUCUGAAGGUGUUC-3' (SEQ ID NO: 2).

[0480] Embodiment 74. The compound of embodiment 71, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-CAATGCCATCCTGGAGTTCCTG-3' (SEQ ID NO: 3).

[0481] Embodiment 75. The compound of embodiment 71, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-UCAAGGAAGAUGGCAUUUCU-3' (SEQ ID NO: 4).

[0482] Embodiment 76. The compound of embodiment 71, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-CGCTGCCCAATGCCAUCC-3' (SEQ ID NO: 5).

[0483] Embodiment 77. The compound of embodiment 71, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-CCTCCGGTTCTGAAGGTGTTC-3' (SEQ ID NO: 6).

[0484] Embodiment 78. The compound of any one of embodiments 1 to 77, wherein the single stranded oligonucleotide comprises one or more modified sugar moieties.

[0485] Embodiment 79. The compound of one of embodiments 1 to 77, wherein each nucleotide of the single-stranded oligonucleotide comprises a modified sugar moiety.

[0486] Embodiment 80. The compound of embodiment 79, wherein the modified sugar moiety comprises a 2' modification.

[0487] Embodiment 81. The compound of embodiment 79 or 80, wherein the 2'-modification is selected from a 2'-fluoro modification, a 2'-O-methyl modification, a 2'-O-methoxyethyl modification, and a bicyclic sugar modification.

[0488] Embodiment 82. A compound according to embodiment 81, wherein the bicyclic sugar modification is selected from a 4'-CH(CH3)-O-2' bond, a 4'-(CH2)2-O-2' bond, a 4'-CH(CH3)-O-2' bond, a 4'-CH(CH2-OMe)-O-2' bond, a 4'-CH(CH2)-N(H)-O-2' bond or a 5'-CH(CH2)-N(CH3)-O-2'.

[0489] Embodiment 83. The compound of embodiment 78, wherein the modified sugar moiety is an unlocked sugar modification.

[0490] Embodiment 84. The compound of embodiment 78, wherein the modified sugar moiety is a morpholino moiety.

[0491] Embodiment 85. The compound of one of embodiments 1 to 84, wherein the single-stranded oligonucleotide comprises one or more modified internucleotide linkages.

[0492] Embodiment 86. The compound of embodiment 85, wherein the modified internucleotide linkage is selected from phosphorothioate linkages and phosphorodiamidate linkages.

[0493] Embodiment 87. The compound of any one of embodiments 1 to 86, wherein each internucleotide bond of the single-stranded oligonucleotide is a chirality-controlled internucleotide bond.

[0494] Embodiment 88. The compound of embodiment 87, wherein the single-stranded oligonucleotide comprises multiple internucleotide bonds in the Sp conformation.

[0495] Embodiment 89. The compound of embodiment 87 or 88, wherein the single stranded oligonucleotide comprises multiple internucleotide bonds in the Rp conformation.

[0496] Embodiment 90. The compound of one of embodiments 72 to 74, wherein each nucleotide of the single-stranded nucleotide comprises a morpholino moiety, and wherein each morpholino moiety is linked by a phosphorodiamidate bond.

[0497] Embodiment 91. The compound of embodiment 72, wherein each nucleotide of the single-stranded nucleotide comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

[0498] Embodiment 92. The compound of embodiment 72, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2'-O-methyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

[0499] Embodiment 93. The compound of embodiment 73, wherein each nucleotide of the single-stranded nucleotides comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

[0500] Embodiment 94. The compound of embodiment 73, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2'-O-methyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

[0501] Embodiment 95. The compound of embodiment 74, wherein each nucleotide of the single-stranded nucleotides comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

[0502] Embodiment 96. The compound of embodiment 74, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2'-O-methyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

[0503] Embodiment 97. The compound of embodiment 75, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2'-O-methyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

[0504] Embodiment 98. The compound of embodiment 75, wherein each nucleotide of the single-stranded nucleotide comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

[0505] Embodiment 99. The compound of embodiment 75, wherein each nucleotide of the single-stranded oligonucleotide comprises a morpholino moiety, and wherein each morpholino moiety is linked by a phosphorodiatmite bond.

[0506] Embodiment 100. A compound according to embodiment 75, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2'-modification, wherein the 2' modification is a 2'-O-methyl modification or a 2'-fluoro modification, and wherein each internucleotide bond is selected from a phosphorothioate bond and a phosphodiester bond in the Sp conformation.

[0507] Embodiment 101. A compound according to embodiment 76, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2' modification, wherein the 2' modification is a 2'-O-methyl modification or a bicyclic sugar modification having a 4'-(CH2)2-O-2' linkage, and wherein each linkage is a phosphodiester linkage.

[0508] Embodiment 102. The compound of embodiment 77, wherein each nucleotide comprises a morpholino moiety, and wherein each morpholino moiety is linked by a phosphorodiamidate linkage.

[0509] Embodiment 103. The compound of one of embodiments 1 to 67, wherein the single-stranded oligonucleotide is a structure selected from the structures in Table 4.

[0510] Embodiment 104. A method comprising contacting a cell with a compound according to one of embodiments 1 to 103.

[0511] Embodiment 105. The method of embodiment 104, wherein said contacting occurs in vitro.

[0512] Embodiment 106. The method of embodiment 104, wherein said contacting occurs in vivo.

[0513] Embodiment 107. A method of inducing dystrophin pre-mRNA exon skipping in a cell, comprising contacting the cell with a compound of one of embodiments 1 to 103.

[0514] Embodiment 108. The method of embodiment 107, wherein the cell is in vitro.

[0515] Embodiment 109. The method of embodiment 107, wherein the cell is in vivo.

[0516] Embodiment 110. A method comprising administering a compound according to one of embodiments 1 to 103 to a subject in need thereof.

[0517] Embodiment 111. A method of treating Duchenne muscular dystrophy comprising administering a compound according to one of embodiments 1 to 103 to a subject in need thereof.

[0518] Embodiment 112. The method of embodiment 110 or 111, wherein the subject is determined to have a mutation in the dystrophin gene that is suitable for exon skipping.

[0519] Embodiment 113. The method of one of embodiments 107 to 112, wherein one or more exons of the pre-mRNA of dystrophin are skipped at an increased level relative to the absence of the compound.

[0520] Embodiment 114. A compound according to any one of Embodiments 1 to 103 for use in therapy.

[0521] Embodiment 115. A compound according to any one of embodiments 1 to 103 for use in the preparation of a medicament.

[0522] Embodiment 116. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound according to any one of embodiments 1 to 103.

[0523] Examples

[0524] The following examples will further describe the present disclosure and are for illustrative purposes only and should not be considered limiting.

[0525] Compounds disclosed her...

Claims

1. A compound having the following structure: in A is a single-stranded oligonucleotide having a nucleobase sequence complementary to a portion of dystrophin pre-mRNA, wherein the single-stranded oligonucleotide is 8 to 30 nucleotides in length; t is an integer from 1 to 5; L 3 Independently is the key, -OPO2-O-, –OP(O)(S)-O-, –O-, -C(O)-, or –OP(O)(N(CH3)2)-N-; L 4 are independently hydroxy-substituted or unsubstituted C1-C 23 Alkylene, or a 2- to 23-membered heteroalkylene substituted or unsubstituted with a substituent selected from hydroxy and oxo; L 5 is an unsubstituted 2- to 20-membered alkylene group, or -L 5A -L 5B -L 5C -L 5D -L 5E -; Where L 5A are independently a bond or unsubstituted C1-C8 alkylene; L 5B are independently a bond, -NHC(O)-, or unsubstituted phenylene; L 5C L is independently a bond, an unsubstituted C2-C8 alkynylene, or an unsubstituted phenylene; 5D are independently a bond or unsubstituted C1-C8 alkylene; and L 5E are independently a bond or -NHC(O)-; L 6 is an unsubstituted 2- to 20-membered alkylene group, or -L 6A -L 6B -L 6C -L 6D -L 6E -; Where L 6A are independently a bond or unsubstituted C1-C8 alkylene; L 6B are independently a bond, -NHC(O)-, or unsubstituted phenylene; L 6C L is independently a bond, an unsubstituted C2-C8 alkynylene, or an unsubstituted phenylene; 6D are independently a bond or unsubstituted C1-C8 alkylene; and L 6E are independently a bond or -NHC(O)-; R1 and R 2 is independently unsubstituted C1-C 25 Alkyl, where R 1 and R 2 At least one of them is unsubstituted C9-C 19 Alkyl; and R 3 is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, –N3, unsubstituted C1-C 20 alkyl, unsubstituted 2-20 membered heteroalkyl, unsubstituted C3-C 10 Cycloalkyl, unsubstituted 3- to 10-membered heterocycloalkyl, unsubstituted C6-C 12 aryl or unsubstituted 5- to 12-membered heteroaryl, The heteroatoms in the heteroalkylene group, heteroalkyl group and heterocycloalkyl group are selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and the heteroatoms in the heteroaryl group are selected from oxygen, nitrogen and sulfur.

2. The compound according to claim 1, wherein t is 1.

3. The compound according to claim 1, wherein t is 2.

4. The compound according to claim 1, wherein t is 3.

5. The compound according to claim 1, wherein one L 3 Attached to the 3' carbon of the oligonucleotide.

6. The compound according to claim 1, wherein one L 3 Attached to the 3' nitrogen of the oligonucleotide.

7. The compound according to claim 1, wherein one L 3 Attached to the 5' carbon of the oligonucleotide.

8. The compound according to claim 1, wherein one L 3 Attached to the 6' carbon of the oligonucleotide.

9. The compound according to claim 1, wherein one L 3 attached to the nucleobase of the oligonucleotide.

10. The compound according to claim 1, wherein L 4 Independently – L 7 -NH-C(O)- or -L 7 -C(O)-NH-, where L 7 It is a hydroxy-substituted or unsubstituted C1-C8 alkylene group.

11. The compound according to claim 1, wherein L 4Independently 12. The compound according to claim 1, wherein L 4 Independently 13. The compound according to claim 1, wherein -L 3 -L 4 -Independently is –OL 7 -NH-C(O)- or -OL 7 -C(O)-NH-, where L 7 are independently hydroxy-substituted or unsubstituted C1-C8 alkylene, hydroxy-substituted or unsubstituted 2-10-membered heteroalkylene, or hydroxy-substituted or unsubstituted 2-10-membered heteroalkenylene; The heteroatoms in the 2-10 membered heteroalkenylene group are selected from oxygen, nitrogen, sulfur, phosphorus and silicon.

14. The compound according to claim 13, wherein -L 3 -L 4 -Independently is –OL 7 -NH-C(O)-, where L 7 and C5-C8 alkylene groups which are independently hydroxy-substituted or unsubstituted.

15. The compound according to claim 14, wherein -L 3 -L 4 - Independently 16. The compound according to claim 1, wherein -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)-, -OP(O)(S)-OL 7 -NH-C(O)-, -OPO2-OL 7 -C(O)-NH- or -OP(O)(S)-OL 7 -C(O)-NH-, where L 7 and C1-C8 alkylene groups which are independently substituted or unsubstituted with hydroxy.

17. The compound according to claim 16, wherein -L 3 -L 4 -Independently -OPO2-OL 7 -NH-C(O)- or -OP(O)(S)-OL 7 -NH-C(O)-, where L 7 and C5-C8 alkylene groups which are independently substituted or unsubstituted with hydroxy groups.

18. The compound according to claim 1, wherein -L3 -L 4 - Independently 19. The compound according to claim 1, wherein -L 3 -L 4 - Independently and attached to the 3' carbon.

20. The compound according to claim 1, wherein -L 3 -L 4 - Independently and attached to the 3' nitrogen of the oligonucleotide.

21. The compound according to claim 1, wherein -L 3 -L 4 - Independently and attached to the 5' carbon of the oligonucleotide.

22. The compound according to claim 1, wherein -L 3 -L 4 - Independently and attached to the 6' carbon of the oligonucleotide.

23. The compound according to claim 18, wherein -L 3 -L 4 - Independently and attached to the nucleobases of the oligonucleotide.

24. The compound according to claim 1, wherein R 3 are independently hydrogen.

25. The compound according to claim 1, wherein L 6 are independently -NHC(O)-, -C(O)NH-, unsubstituted C1-C 20 alkylene, or unsubstituted 2 to 20 membered heteroalkylene.

26. The compound according to claim 25, wherein L 6 is independently -NHC(O)-.

27. The compound according to claim 1, wherein L 6 Independently is the key, 28. The compound according to claim 1, wherein L 5 are independently -NHC(O)-, -C(O)NH-, unsubstituted C1-C 20 alkylene, or unsubstituted 2- to 20-membered heteroalkylene.

29. The compound according to claim 1, wherein L 5 is independently -NHC(O)-.

30. The compound according to claim 1, wherein L 5 Independently is the key, 31. The compound according to claim 1, wherein R 1 is an unsubstituted C1-C 17 alkyl.

32. The compound according to claim 1, wherein R 1 is unsubstituted C 11 -C 17 alkyl.

33. The compound according to claim 1, wherein R 1 is unsubstituted C 13 -C 17 alkyl.

34. The compound according to claim 1, wherein R 1 is unsubstituted C 14 -C 15 alkyl.

35. The compound according to claim 1, wherein R 1 It is an unsubstituted unbranched C1-C 17 alkyl.

36. The compound according to claim 1, wherein R 1 is an unsubstituted unbranched C 11 -C 17 alkyl.

37. The compound according to claim 1, wherein R 1 is an unsubstituted unbranched C 13 -C 17 alkyl.

38. The compound according to claim 1, wherein R 1 is an unsubstituted unbranched C 14 -C 15 alkyl.

39. The compound according to claim 1, wherein R 1 It is an unsubstituted unbranched saturated C1-C 17 alkyl.

40. The compound according to claim 1, wherein R1 is an unsubstituted unbranched saturated C 11 -C 17 alkyl.

41. The compound according to claim 1, wherein R 1 is an unsubstituted unbranched saturated C 13 -C 17 alkyl.

42. The compound according to claim 1, wherein R 1 is an unsubstituted unbranched saturated C 14 -C 15 alkyl.

43. The compound according to claim 1, wherein R 2 is an unsubstituted C1-C 17 alkyl.

44. The compound according to claim 1, wherein R 2 is unsubstituted C 11 -C 17 alkyl.

45. The compound according to claim 1, wherein R 2 is unsubstituted C 13 -C 17 alkyl.

46. ​​The compound according to claim 1, wherein R 2 is unsubstituted C 14 -C 15 alkyl.

47. The compound according to claim 1, wherein R 2 It is an unsubstituted unbranched C1-C 17 alkyl.

48. The compound according to claim 1, wherein R 2 is an unsubstituted unbranched C 11 -C 17 alkyl.

49. The compound according to claim 1, wherein R 2 is an unsubstituted unbranched C 13 -C 17 alkyl.

50. The compound according to claim 1, wherein R 2 is an unsubstituted unbranched C 14 -C 15 alkyl.

51. The compound according to claim 1, wherein R 2 It is an unsubstituted unbranched saturated C1-C 17 alkyl.

52. The compound according to claim 1, wherein R 2is an unsubstituted unbranched saturated C 11 -C 17 alkyl.

53. The compound according to claim 1, wherein R 2 is an unsubstituted unbranched saturated C 13 -C 17 alkyl.

54. The compound according to claim 1, wherein R 2 is an unsubstituted unbranched saturated C 14 -C 15 alkyl.

55. The compound of claim 1, wherein the single stranded oligonucleotide induces exon skipping of the dystrophin pre-mRNA.

56. The compound of claim 55, wherein the nucleobase sequence of the single-stranded oligonucleotide is complementary to a splice donor site, a splice acceptor site, an exonic splicing enhancer (ESE), a splice branch point, an exon recognition sequence, or a splicing enhancer of the dystrophin pre-mRNA.

57. The compound of claim 55, wherein the nucleobase sequence of the single-stranded oligonucleotide is complementary to an annealing site selected from:

58. The compound of claim 1, wherein the single-stranded oligonucleotide is 15 to 30 nucleotides in length.

59. The compound of claim 1, wherein the single-stranded oligonucleotide is 20 to 30 nucleotides in length.

60. The compound of claim 1, wherein the single stranded oligonucleotide is 25 to 30 nucleotides in length.

61. The compound of claim 1, wherein the nucleobase sequence of the single-stranded oligonucleotide is selected from The nucleobase sequences of SEQ ID NO: 1 to SEQ ID NO:

210.

62. The compound of claim 61, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-CUCCAACAUCAAGGAAGAUGGCAUUUCUAG-3' (SEQ ID NO: 1).

63. The compound of claim 61, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-GUUGCCUCCGGUUCUGAAGGUGUUC-3' (SEQ ID NO: 2).

64. The compound of claim 61, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-CAATGCCATCCTGGAGTTCCTG-3' (SEQ ID NO: 3).

65. The compound of claim 61, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-UCAAGGAAGAUGGCAUUUCU-3' (SEQ ID NO: 4).

66. The compound of claim 61, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-CGCTGCCCAATGCCAUCC-3' (SEQ ID NO: 5).

67. The compound of claim 61, wherein the nucleobase sequence of the single-stranded oligonucleotide is 5'-CCTCCGGTTCTGAAGGTGTTC-3' (SEQ ID NO: 6).

68. A compound according to any one of claims 1 to 67, wherein the single stranded oligonucleotide comprises one or more modified sugar moieties.

69. The compound of claim 1, wherein each nucleotide of the single-stranded oligonucleotide comprises a modified sugar moiety.

70. The compound of claim 69, wherein the modified sugar moiety comprises a 2' modification.

71. The compound of claim 70, wherein the 2'-modification is selected from a 2'-fluoro modification, a 2'-O-methyl modification, a 2'-O-methoxyethyl modification, and a bicyclic sugar modification.

72. A compound according to claim 71, wherein the bicyclic sugar modification is selected from a 4'-CH(CH3)-O-2' bond, a 4'-(CH2)2-O-2' bond, a 4'-CH(CH3)-O-2' bond, a 4'-CH(CH2-OMe)-O-2' bond, a 4'-CH(CH2)-N(H)-O-2' bond, or a 5'-CH(CH2)-N(CH3)-O-2'.

73. The compound of claim 68, wherein the modified sugar moiety is an unlocked sugar modification.

74. The compound of claim 68, wherein the modified sugar moiety is a morpholino moiety.

75. The compound of claim 1, wherein the single stranded oligonucleotide comprises one or more modified internucleotide bonds.

76. The compound of claim 75, wherein the modified internucleotide bond is selected from a phosphorothioate bond and a phosphorodiamidate bond.

77. The compound of claim 1, wherein each internucleotide bond of the single-stranded oligonucleotide is a chirality-controlled internucleotide bond.

78. The compound of claim 77, wherein the single-stranded oligonucleotide comprises a plurality of internucleotide bonds in the Sp conformation.

79. The compound of claim 77, wherein the single-stranded oligonucleotide comprises multiple internucleotide bonds in the Rp conformation.

80. The compound of claim 62, wherein each nucleotide of the single stranded oligonucleotide comprises a morpholino moiety, and wherein each morpholino moiety is linked by a phosphorodiamidate bond.

81. The compound of claim 62, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleotide bond is a phosphorothioate bond.

82. The compound of claim 62, wherein each nucleotide of the single stranded oligonucleotide comprises a 2'-O-methyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

83. The compound of claim 63, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

84. The compound of claim 63, wherein each nucleotide of the single stranded oligonucleotide comprises a 2'-O-methyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

85. The compound of claim 64, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

86. The compound of claim 64, wherein each nucleotide of the single stranded oligonucleotide comprises a 2'-O-methyl sugar modification, and wherein each internucleotide bond is a phosphorothioate bond.

87. The compound of claim 65, wherein each nucleotide of the single stranded oligonucleotide comprises a 2'-O-methyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

88. The compound of claim 65, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleotide linkage is a phosphorothioate linkage.

89. The compound of claim 65, wherein each nucleotide of the single stranded oligonucleotide comprises a morpholino moiety, and wherein each morpholino moiety is linked by a phosphorodiamidate bond.

90. The compound of claim 65, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2'-modification, wherein the 2' modification is a 2'-O-methyl modification or a 2'-fluoro modification, and wherein each internucleotide bond is selected from a phosphorothioate bond in the Sp conformation, and a phosphodiester bond.

91. A compound according to claim 66, wherein each nucleotide of the single-stranded oligonucleotide comprises a 2' modification, wherein the 2' modification is a 2'-O-methyl modification or a bicyclic sugar modification having a 4'-(CH2)2-O-2' bond, and wherein each bond is a phosphodiester bond.

92. The compound of claim 67, wherein each nucleotide comprises a morpholino moiety, and wherein each morpholino moiety is linked by a phosphorodiamidate bond.

93. The compound of claim 1, wherein the single-stranded oligonucleotide is selected from the following structures:

94. A method comprising contacting a cell in vitro with a compound according to one of claims 1 to 93.

95. A method of inducing dystrophin pre-mRNA exon skipping in a cell, comprising contacting the cell in vitro with a compound according to one of claims 1 to 93.

96. Use of a compound according to claim 1 in the preparation of a medicament for treating Duchenne muscular dystrophy.

97. The use according to claim 96, comprising administering the compound according to claim 1 to a subject in need thereof, wherein the subject is determined to have a mutation in the dystrophin gene suitable for exon skipping.

98. The use according to claim 96 or 97, wherein one or more exons of the pre-mRNA of dystrophin are skipped at an increased level relative to the absence of the compound.

99. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound according to claim 1.